Archive for the ‘Genetic Testing’ Category

Predictive Genetic Testing and Consumer/Wellness Genomics Market: Snapshot

Genetic testing comprises examination of ones DNA. The term DNA refers to the chemical database that is responsible for conveying the instructions for functions that need to be performed by the body. Genetic testing is capable of revealing changes or mutations in the genes of living beings, which might result in any kind of disease or illness in the body.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1274

Predictive genetic testingrefers to the utilization of genetic testing methods in an asymptomatic individual to make a prediction about risk of contacting particular disease in future. These tests are regarded as representation of emerging class of medical tests, which differ in fundamental ways from the usual diagnostic tests.

The global predictive genetic testing and consumer/wellness genomics marketis likely to gather momentum owing to the benefits offered by predictive genetic testing.

The benefits of predictive genetic testing are

The global predictive genetic testing and consumer/wellness genomics marketis influenced by reducing cost of genetic sequencing and technological advancement in the field of genetics. North America is expected to emerge as a prominent region for the global predictive genetic testing and consumer/wellness genomics market in years to come due to high adoption rates of latest technologies in all fields.

Over centauries human DNA has undergone tremendous alteration due to evolutionary and lifestyle changes. They have led to both, advantages and disadvantages over the years. Some have given the mankind a deserving edge over other creatures while the others have led to disorders and diseases. Predictive genetic testing and consumer/wellness genomics market thrives on the growing demand for understanding the lineage of a certain gene pool to identify disorders that could manifest in the later or early stage of a human life. The surging demand for understanding the family history or studying the nature of certain diseases has given the global market for predictive genetic testing and consumer/wellness genomics market adequate fodder for growth in the past few years.

This new class of medical tests are aimed at reducing the risk of morbidity and mortality amongst consumers. The thorough surveillance and screening of a certain gene pool can allow an individual to avoid conditions that disrupt normal existence through preventive measures. The clinical utility of these tests remains unassessed. Therefore, increasing research and development by pharmaceutical companies to develop new drugs by understanding diseases and disorders is expected to favor market growth.

Unlike conventional diagnostic testing, predictive genetic testing identifies the risk associated with potential conditions. In certain cases it is also capable of stating when the disease may appear and the how severe will it be. Thus, this form of testing is expected to allow consumers to take up wellness measurements well in time to lead a life of normalcy, characterized by good health.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1274<ype=S

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Overview

Predictive genetic testing are used to identify gene mutations pertaining to the disorders that surface at a considerably later stage in life after birth. These tests are particularly beneficial for people from a family with a history of genetic disorder, although they themselves show no symptoms of the disorder at the time of testing. Genetic testing promises to revolutionize the healthcare sector, providing crucial diagnostic details related to diverse verticals such as heart disease, autism, and cancer. As the healthcare sector touches new peaks, the global predictive genetic testing and consumer/wellness genomics market is projected to expand at a healthy growth rate during the forecast period of 2017 to 2025.

This report on the global market for predictive genetic testing and consumer/wellness genomics analyzes all the important factors that may influence the demand in the near future and forecasts the condition of the market until 2025. It has been created using proven research methodologies such as SWOT analysis and Porters five forces. One of the key aspect of the report is the section on company profiles, wherein several leading players have been estimated for their market share and analyzed for their geographical presence, product portfolio, and recent strategic developments such as mergers, acquisitions, and collaborations.

The global predictive genetic testing and consumer/wellness genomics market, on the basis of test type, can be segmented into predictive testing, consumer genomics, and wellness genetics. The segment of predictive testing can be sub-segmented into genetic susceptibility test, predictive diagnostics, and population screening programs, whereas the segment of wellness genetics can be further divided into nutria genetics, skin and metabolism genetics, and others.

By application, the market can be segmented into breast and ovarian cancer screening, cardiovascular screening, diabetic screening and monitoring, colon cancer screening, Parkinsons or Alzheimers disease, urologic screening or prostate cancer screening, orthopedic and musculoskeletal screening, and other cancer screening. Geographically, the report studies the opportunities available in regions such as Asia Pacific, Europe, North America, and the Middle East and Africa.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Trends and Opportunities

Increasing number of novel partnership models, rapidly decreasing cost of genetic sequencing, and introduction of fragmented point-solutions across the genomics value chain as well as technological advancements in cloud computing and data integration are some of the key factors driving the market. On the other hand, the absence of well-defined regulatory framework, low adoption rate, and ethical concerns regarding the implementation, are expected to hinder the growth rate during the forecast period. Each of these factors have been analyzed in the report and their respective impacts have been anticipated.

Currently, the segment of predictive genetic cardiovascular screening accounts for the maximum demand, and increased investments in the field is expected to maintain it as most lucrative segment. On the other hand, more than 70 companies are currently engaged in nutrigenomics, which is expected to further expand the market.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Regional Outlook

Owing to robust healthcare infrastructure, prevalence of cardiovascular diseases, and high adoptability rate of new technology makes North America the most lucrative region, with most of the demand coming from the country of the U.S. and Canada. Several U.S. companies hold patents, which further extends the outreach of the market in the region of North America.

Companies mentioned in the research report

23andMe, Inc, BGI, Genesis Genetics, Illumina, Inc, Myriad Genetics, Inc, Pathway Genomics, Color Genomics Inc., and ARUP Laboratories are some of the key companies currently operating in global predictive genetic testing and consumer/wellness genomics market. Various forms of strategic partnerships with operating company and smaller vendors with novel ideas helps these leading players maintain their position in the market.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1274

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Follow this link:
PREDICTIVE GENETIC TESTING AND CONSUMER/WELLNESS GENOMICS MARKET TRENDS AND DYNAMIC 2025 - Scientect

Thursday, August 27, 2020

Does payer coverage of genomic testing drive utilization? That is the question The Personalized Medicine Coalition (PMC) asked and answered in its recent report Understanding Genomic Testing Utilization and Coverage in the US (Study). PMCs Study, conducted in collaboration with BlueCross/BlueShield Association, Concert Genetics, and Illumina, sought to uncover patterns between the clinical use of genomic testing and payer coverage. Three clinical areas were studied: noninvasive prenatal testing (NIPT) in prenatal screening, whole exome sequencing (WES) in patients with rare and undiagnosed genetic diseases, and comprehensive genomic profiling (CGP) of tumors in patients with advanced cancer.

Four key findings were highlighted in the Study.1In sum, payer coverage of medically appropriate genomic tests is increasing, but this increase in coverage did not correspond with higher utilization of testing across the United States. As such, medically appropriate genetic testing was inconsistently utilized across the United States. While inconsistent coverage and reimbursement policies are barriers to patient access to testing, the Study concluded that these policies do not entirely explain inconsistent test utilization. Other utilization barriers were identified for further attention.

The Study acknowledged that obtaining payer coverage and reimbursement for genomic testing is one of several challenges to providing patients access to these medically important tests.2However, other challenges were identified that prevent full test access. These included a lack of clarity and consistency of payer coverage policies within and between states and across clinical areas. Identified barriers to test utilization were: socioeconomic determinants of health (such as the distance patients must travel to access genomic medical specialists), cultural and community factors (including known racial and ethnic health disparities across the health care systems), and data security and privacy concerns. Lack of awareness, knowledge and education of personalized medicine among health care providers and patients were also identified as ongoing challenges to full test utilization.

There is no doubt that research and development of personalized medicine diagnostics and therapies have been increasing but room for improvement remains. As noted by the Study:

Over the last 20 years, a steadily growing number of genetic biomarkers that contribute to disease have been discovered. New targeted therapies being developed to improve outcomes for responder patients add to this value proposition. However, utilization rates for medically appropriate NIPT, WES, and CGP genomic testing are inconsistent and variable even when favorable coverage policies exist. The full value of genomic testing cannot be realized unless utilization increases."3

The authors of the Study encourage proponents of personalized medicine to continue to develop and disseminate evidence supporting the clinical and economic benefits of genomic testing. Additional studies that evaluate each identified barrier and its impact on access and utilization will help address and remove barriers to access for every patient that needs it.

-------------------------------------------------------

1Study at page 5.2Study at page 21.3Study at page 22.

2020 Foley & Lardner LLPNational Law Review, Volume X, Number 240

See the original post here:
Payer Coverage Drive Genomic Test Utilization in the US? - The National Law Review

The research report on the global DTC Genetic Testing Market offers an all-encompassing analysis of recent and upcoming states of this industry which also analyzes several growth strategies for market growth. The DTC Genetic Testing report also focuses on the comprehensive study of the industry environment, and industry chain structure extensively. The DTC Genetic Testing report also sheds light on major factors including leading vendors, growth rate, production value, and key regions.

Request for a sample report here @:

https://www.globalmarketers.biz/report/life-sciences/global-dtc-genetic-testing-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/153716#request_sample

Top Key Players:

Color GenomicsLaboratory Corporation of AmericaMapMyGenomeGene by Gene23andMeAfrican AncestryHelixWeGeneMyriad GeneticsPathway GenomicsQuest DiagnosticsThermo Fisher

DTC Genetic Testing Market Fragment by Areas, regional examination covers

United States, Canada, Germany, UK, France, Italy, Russia, Switzerland, Sweden, Poland, , China, Japan, South Korea, Australia, India, Taiwan, Thailand, Philippines, Malaysia, Brazil, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World.

The DTC Genetic Testing Market report introduces the industrial chain analysis, downstream buyers, and raw material sources along with the correct comprehensions of market dynamics. The DTC Genetic Testing Market report is articulated with a detailed view of the Global DTC Genetic Testing industry including Global production sales, Global revenue, and CAGR. Additionally, it offers potential insights about Porters Five Forces including substitutes, buyers, industry competitors, and suppliers with genuine information for understanding the Global DTC Genetic Testing Market.

Get Impressive discount @:

https://www.globalmarketers.biz/discount_inquiry/discount/153716

Market segment by Type, the product can be split into:

Disease Risk and HealthAncestry or GenealogyKinshipLifestyle

Market segment by Application, split into:

On-line SalesDoctors Office

The DTC Genetic Testing Market study projects viability analysis, SWOT analysis, and various other information about the leading companies operating in the Global DTC Genetic Testing Market provide a complete efficient account of the viable environment of the industry with the aid of thorough company profiles. However, DTC Genetic Testing research examines the impact of current market success and future growth prospects for the industry.

Inquire Before Buying @:

https://www.globalmarketers.biz/report/life-sciences/global-dtc-genetic-testing-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/153716#inquiry_before_buying

In this study, the years considered to estimate the market size of DTC Genetic Testing are as follows:

Table of Contents:

Get Full Table of Content @:

https://www.globalmarketers.biz/report/life-sciences/global-dtc-genetic-testing-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/153716#table_of_contents

Go here to read the rest:
Global DTC Genetic Testing Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2026 - Scientect

SAN CARLOS, Calif., Aug. 27,2020 /PRNewswire/ --Natera, Inc.(NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a collaborative agreement with Mass General Cancer Center (MGCC) of Massachusetts General Hospital, related to an investigator-initiated multi-center, Phase II randomized clinical trial of Ribociclib (Kisqali), a CDK4/6 inhibitor, for the treatment of ER-positive breast cancer (LEADER), the first circulating tumor DNA (ctDNA)-based study of a CDK4/6 inhibitor in ER-positive early stage breast cancer.

LEADER (part II) will randomize patients who have localized post-menopausal breast cancer with detectable ctDNA after surgery as evidence of minimal residual disease (MRD), and will determine tumor molecular response after Ribociclib in combination with endocrine therapy versus endocrine therapy alone. Natera's Signateratest will be used to determine patient enrollment eligibility based on presence of ctDNA via longitudinal monitoring and to evaluate response based on ctDNA clearance as the primary endpoint.

"With the overwhelming evidence that patients with detectable ctDNA are at high risk for relapse, our goal is to investigate a new treatment strategy for these patients and reduce risk of disease recurrence," said Aditya Bardia, MD, MPH, the study's principal investigator from MGCC, Harvard Medical School. "Since the LEADER trial is in the MRD setting, it is critical to use a highly sensitive assay."

Breast cancer remains the second leading cause of cancer death in women in the United States,1 and the U.S. Food and Drug Administration (FDA) has approved Ribociclib in combination with aromatase inhibitors as a first-line treatment option for advanced/metastatic (stage IV) disease.

"We are proud to partner with Massachusetts General Hospital on this exciting new approach of using Signatera personalized ctDNA analysis for enrollment and evaluation of treatment response to CDK4/6 inhibitors in the MRD setting," said Alexey Aleshin, MD, MBA, Natera's Senior Medical Director for Oncology."We believe this collaboration may pave the way for more trials using ctDNA to study the effectiveness of an investigational drug in early stage breast cancer."

About Signatera

Signatera is a custom-built ctDNA test for treatment monitoring and MRD assessment in patients previously diagnosed with cancer. The test is available for clinical and research use, and it was granted Breakthrough Device Designation by the FDA in 2019. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor. This maximizes accuracy for detecting the presence or absence of residual disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Unlike a standard liquid biopsy, Signatera is not intended to match patients with any particular therapy. Rather, it is intended to detect and quantify how much cancer is left in the body, to detect recurrence earlier and to help optimize treatment decisions. Signatera's test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.Signatera has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.

About Natera

Naterais a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to oncologists, obstetricians, and transplant physicians, as well as to researchers and biopharmaceutical companies. For more information, visit natera.com. Follow Natera on LinkedIn.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical or other studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at http://www.natera.com/investorsand http://www.sec.gov.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350Media: Paul Greenland, VP of Corporate Marketing, [emailprotected]

References

1. How Common Is Breast Cancer? The American Cancer Society. Updated January 8,2020. Accessed July 14, 2020. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html.

SOURCE Natera, Inc.

http://www.natera.com

See the rest here:
Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer -...

DALLAS--(BUSINESS WIRE)--Avero Diagnostics, a physician-owned laboratory, is pleased to announce the expansion of its COVID-19 testing portfolio with the addition of the Roche Elecsys Anti-SARS-CoV-2 antibody test. Serological testing supports the Centers for Disease Control and Prevention (CDC) efforts to more accurately understand how many people have been infected with SARS-CoV-2, the virus that causes COVID-19, and how it is spreading. This offering, available now, will complement Averos existing COVID-19 molecular testing program, which Avero launched in May 2020 to support the diagnostic needs of area hospitals, health systems, multi-specialty family practices, urgent care centers, and county health departments.

As the medical and scientific communities work to understand and stop the spread of COVID-19, serological testing serves as a piece of the very complex puzzle, said Trae Mattison, MD, Managing Partner, Avero Diagnostics. By expanding our COVID-19 testing services, we are not only supporting the need for serology testing in our community, we are also contributing to the national effort to understand the spread of the SARS-CoV-2 virus.

A serological test, often called antibody testing, is used to determine whether a person may have had a past infection with the virus that causes COVID-19. This test uses a blood sample to provide qualitative detection of high-affinity antibodies to SARS-CoV-2, to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. This assay enriches detection of higher affinity antibodies which are more likely to be specific for SARS-CoV-2. While this assay in principle can detect antibodies of all isotypes (i.e., IgG, IgA, IgM), it preferentially detects IgG antibodies. This test is recommended for individuals 14 days post-symptom onset, or five to seven days following exposure to individuals with confirmed COVID-19.

Avero Diagnostics CLIA-certified and CAP-accredited laboratory is using the Roche immunoassay for the qualitative detection of antibodies against SARS-CoV-2. The test is an electro-chemiluminescence immunoassay with 99.8% specificity. Avero can initially process approximately 800 tests per day, with the potential to scale up capacity based on demand. Avero expects to provide results to ordering providers within 24 to 48 hours.

For more information, visit http://www.averodx.com.

About Avero Diagnostics

Avero Diagnostics is a physician-owned laboratory and an affiliate of Progenity, Inc. (Nasdaq: PROG), dedicated to providing high quality anatomic pathology, molecular pathology, and genetic testing services to physicians and their patients. Avero Diagnostics provides sub-specialized pathology services in the areas of breast, gynecologic, gastrointestinal, molecular, and urologic pathology. The company also offers specialized testing services in genetic carrier testing and noninvasive prenatal screening. Avero is focused on improving healthcare delivery to patients through the research and development of novel diagnostic equipment and assays, offering a faster and more accurate result. Avero Diagnostics vision is to lead the healthcare industry in the delivery of anatomic pathology, molecular pathology and genetic testing. For more information, please visit http://www.averodx.com.

Read the original:
Avero Diagnostics Expands COVID-19 Testing Capabilities with Launch of Serology Testing - Business Wire

News

Genetic sequencing revealed the man in Hong Kong had been infected with two different strains of the coronavirus.

Nothing too surprising. I suspect reinfection is happening a lot more often than we have bothered to find yet. Itll be happening more frequently in areas where theres lots of transmission.That is Associate Professor Ian Mackay, a prominent virologist from the University of Queensland, commenting on a pre-print study, released on 24 August, of the worlds first confirmed case of COVID-19 reinfection.The 33-year-old man first tested positive on 26 March in Hong Kong. He was hospitalised with mild symptoms including cough, sore throat, fever and headache.Then on 15 August 142 days after the first infection the man tested positive again, this time during a routine entry screening to Hong Kong airport after having travelled to Spain via the UK. The man was hospitalised again, but remained asymptomatic.The research team from The University of Hong Kong, led by microbiologist Dr Kelvin Kai-Wang To, used genetic testing to analyse viral samples taken from the patient collected 10 days after his symptoms emerged during the first episode, and one day after he was hospitalised the second time.It shows that some people do not have lifelong immunity, Dr To said. We dont know how many people can get reinfected. There are probably more out there.As a result, he said patients with previous COVID-19 infection should continue to comply with epidemiological control measures, such as social distancing and mask-wearing.

Two additional cases of reinfection, one in the Netherlands and another in Belgium, were confirmed by virologists via genetic testing on Tuesday, according to AAP.The prospect of reinfection has been speculated throughout the pandemic so far, with numerous anecdotal reports. But UHKs pre-print study, accepted for publication in the journal Clinical Infectious Diseases, is the first to confirm reinfection with rigorous testing.The discovery is also in line with recent studies that show antibodies start to wane within around three months.But rather than raise alarm, Associate Professor Mackay says this is a sign of the body functioning effectively.Thats what the body does; it makes its initial response, it develops the immune cells, but it doesnt keep producing antibodies to every single thing or else our blood would be like pea soup it would be sick with antibodies and proteins, he told newsGP.So most of the time youll develop those antibodies, theyll go away, but youre left with the traces of immunity that will fire up again should you ever be challenged by that same virus.Researchers used genetic sequencing to confirm reinfection, showing infections from two viral strains of SARS-CoV-2 that were clearly different.Associate Professor Mackay says while viral mutation is common, it can create confusion and anxiety outside of the scientific community.In this case, the second infection was a slightly different genetic code to the first. It is still the same virus, it all falls under SARS-CoV-2, but theyre just subtly different, he explained.A virus is really a cluster of subtly different variants of that virus, and it is constantly changing. So if I was to be infected with SARS-CoV-2, I would have a lot of different variants as they vie for the position to get the next cell and replicate the fastest to then be transmitted.

VirologistAssociate Professor Ian Mackay suspects reinfection is happening a lot more often than we have bothered to find yet.

With many of the worlds borders closed and travel otherwise significantly restricted, the virologist says such control measures have an impact on a virus evolution similar to that of animal species that are living in isolation.For example, on an island like the Galapagos youll see specific animals that havent evolved the same way in other places because theyve been isolated, while theyve replicated generations of new offspring, Associate Professor Mackay said.Viruses are doing the same thing, and each time they produce new offspring they can be subtly tuned to be more adapted to their environment, which might be that person.They might have changed some of the things that that persons immune response attacks so they can escape from it, or they may have found that one of those particular viruses that came in had the ability to replicate a little faster, so it overtook some of the other viruses.So youve got all this variation going on, and the fittest viruses are the ones that are likely to be coughed or sneezed out at the other end. And then theyll go on and start the whole process in the next patient.As is seen in the study, he says scientists have the ability to track each of these changes through genomic sequencing.We can sequence the entire 30,000 nucleotides the library of its life and see how those changes have occurred from person-to-person first, country-to-country, plane-trip-to-city, whatever it might be when you compare A to B, youll see those differences, Associate Professor Mackay said.Could these mutations, however, have implications for the development of a vaccine?If there is significant change in the sequence being used to create the vaccine, it is possible but unlikely, according to Associate Professor Mackay.Theres no sign that thats been the case here [in Australia], or in any of the work done so far, he said.It seems like all of the vaccines that are underway do mount the right kind of immune response that will still take out all the different variants of this SARS-CoV-2 wherever it might be, whether its a new mutant or whatever.The fact the mans second infection was less severe than the first makes the study a case in point.This is kind of a way of testing that in this particular case youve got two different genetic variants, but it looks like the immunity from the first infection prevented the second infection causing the patient to get ill, Associate Professor Mackay said.So they were, if you like, vaccinated by the first case and disease was prevented in the second infection.Professor Nigel McMillan, Director in Infectious Diseases and Immunology at Menzies Health Institute Queensland at Griffith University, says the findings indicate that countries such as Sweden relying on natural herd immunity are on the wrong path.This will not be effective, he said.Going forward what we need to know is how long T-cell immunity lasts in naturally infected people and, more importantly, how long vaccine responses last as this will determine how often we need to be vaccinated.Associate Professor Mackay agrees. He believes a vaccine is still the way out of the pandemic for countries with high transmission, as well as others like Australia.If we all get vaccinated and we have some immunity develop, then well develop some memory and that means when we get infected a second time, we will hopefully see the same kind of thing that happens here [in the study], he said. Which is to say, we could still be infected out in the wild if we all were to meet up with the virus again after wed been vaccinated, but we wouldnt get severely sick or we wouldnt die.If it was to produce another kind of immunity that prevented moderate or even mild illness, fantastic.But, right now, we just want to prevent that severe disease and death.Log in below to join the conversation.

coronavirus COVID-19 immunity reinfection

Originally posted here:
newsGP - What are the implications of the first case of COVID reinfection? - RACGP

SINGAPORE: There is"no known" caseof COVID-19 reinfection in Singapore to date, andthe Ministry of Health (MOH) is "actively investigating" the possibilityof reinfectionamong those who have recovered from the disease.

Following reports of recoveredCOVID-19 casesin Hong Kong, Belgium and the Netherlands becoming reinfected with the coronavirus, an MOH spokesperson said on Thursday (Aug 27) that the ministrycontinues to review global and local clinical research and evidence on COVID-19 reinfection.

MOH will "monitor the situation closely", said thespokespersonin response to CNA queries.

We have also been actively investigating the possibility of reinfection among persons who have recovered from COVID-19, when they seek subsequent medical care for acute respiratory infectionsymptoms," the spokesperson added.

On Monday, researchers at the University of Hong Kong said a Hong Kong man who recovered from COVID-19 was reinfected four-and-a-half months later.

It was the first documented instance of human reinfection.The 33-year-old man was cleared of COVID-19 and discharged from hospital in April, but tested positive again after returning from Spain via Britain on Aug15.

The patient had appeared to be previously healthy, researchers said in the paper, which was accepted by the international medical journal Clinical Infectious Diseases.

He was found to have contracted a different coronavirus strain from the one he had previously contracted and remained asymptomatic for the second infection.

The finding does not mean taking vaccines will be useless,DrKai-Wang To, one of the leading authors of the paper, told Reuters.

"Immunity induced by vaccination can be different from those induced by natural infection," he said."(We) will need to wait for the results of the vaccine trials to see if how effective vaccines are."

World Health Organization (WHO) epidemiologist Maria Van Kerkhove said on Monday that there was no need to jump to any conclusions, in response to the Hong Kong case.

On Tuesday, a patient in the Netherlands and another in Belgium were confirmedto have been reinfected with the coronavirus, reported Dutch national broadcaster NOS, citing virologists.

NOS cited virologist Marion Koopmans as saying the Dutch patient was an older person with a weakened immune system.

She said that cases where people have been sick with the virus a long time, and it then flares up, are better known.But a true reinfectionrequires genetic testing of the virus in both the first and second infections to see whether the two instances of the virus differ slightly.

Koopmans, an adviser to the Dutch government, said reinfections had been expected.

"That someone would pop up with a reinfection, it doesn't make me nervous," she said. "We have to see whether it happens often."

The Belgian patient had mild symptoms, NOS reportedvirologist Marc Van Ranst as saying. He said the case shows that antibodies the patient developed during the first exposure were not enough to prevent a second infectionwith aslightly different variant of the virus.

An infectious disease specialist in China's expert group for COVID-19 treatment, Wang Guiqiang, also offered several explanations about reinfection, as reported by Reuters.

One explanation was that the virus still existed in the lungs of patients but was not detected in samples taken from upper parts of the respiratory tract, he said. Other possible causes could include thelow sensitivity of tests and weak immunity that could lead to persistent positive results.

Downloadourappor subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:https://cna.asia/telegram

Here is the original post:
No known case of COVID-19 reinfection in Singapore, says MOH - CNA

While pre- and post-test education on genetic testing helped to educate patients, recent study findings may also highlight the way that telemedicine is revolutionizing the space, according to Kelly Morgan, MS, CGC.

In a recent study, presented at the 2020 ASCO Virtual Scientific Program, the BRCA Founder OutReach (BFOR) offered pre-testing online education with posttest engagement of primary care providers, which appeared to be effective in educating both patients and providers alike.

In an interview with CancerNetwork, Morgan, a genetic counselor at Memorial Sloan Kettering Cancer Center, explained how telemedicine is changing the future of genetic testing.

Transcription:

The current focus is going to be continuing to survey our participants and then analyze and report out our findings. These are sort of our first set of early results. But the goal from there is, there's a lot of different ways in which this information can probably be used in terms of next steps.

One of the things I mentioned was the idea of new ways to engage primary care providers. So that's certainly an area of interest. One thing I didn't mention, but it's also kind of along the lines of where we want to go is we were very happy with the recruitment that we achieved, but at the same time, we think this tool could be used even more broadly, potentially. So finding ways to better distribute this information and engage a broader number of participants. And then lastly, the immediate context for this is thinking about how this model may work for population screening in the Ashkenazi Jewish group. But there are ways that we could pivot this to other situations as well. So, whether that be things like testing family members for an unknown mutation, or maybe there are other groups with predominant risk factors where this model could work as well. So, I think that once we better understand the long term medical outcomes of participants, we will be able to continue to think about different ways that we can improve and change the model and then apply it further in this context and others as well.

I think, now more than ever, is a time where there's almost a digital revolution, if you will, and a lot of technology in the forefront. So, from our perspective, our goal is to find a way to leverage technology in the context of medicine and use it for better. So there's always a lot going on in terms of many different ways to access testing direct to consumer testing. And, you know, if and when this sort of convenience can be combined with medicine, I think there's a lot of opportunities for improved patient care through that partnership.

See original here:
Kelly Morgan, MS, CGC, the Future of Telemedicine and Genetic Testing - Cancer Network

Direct-to-Consumer (DTC) Genetic Testing Market Introduction

Direct-to-consumer (DTC) genetic testing refers to genetic testing that provides people with their genetic information wherein involvement of healthcare professional or Health Insurance Company is not necessary. While a number of companies are offering the direct-to-consumer (DTC) genetic testing, it is spreading awareness regarding genetic diseases that can be prevented in time. Direct-to-consumer (DTC) genetic testing also offers personalized information about overall health, potential disease risks and other genetic traits.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4770

The direct-to-consumer (DTC) genetic testing market is expected to witness significant growth in the future on the back of rising awareness among patients to go for early diagnosis and obtain in-time treatment. As the prevalence of genetic diseases and rare disorders is increasing across the globe, application of direct-to-consumer (DTC) genetic testing is expected to rise significantly in the coming years.

Direct-to-Consumer (DTC) Genetic Testing Market Notable Developments

Some of the most prominent competitors operating in the competitive landscape of global direct-to-consumer (DTC) genetic testing market include

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=4770

Direct-to-Consumer (DTC) Genetic Testing Market Dynamics

Opportunities for Manufacturers as FDA Relieves Regulatory Hurdles

In June 2018, the U.S. FDA relieved some of the regulatory hurdles for manufacturers of the direct-to-consumer (DTC) genetic testing for health risk. As per the new regulatory updates, manufacturers, after receiving the first premarket approval for genetic health risk (GHR) test can commercialize the test without the requirement of additional review. GHR tests provide consumers with genetic risk information to consumers, however, it does not determine whether the person is at risk of developing a disease or a condition. While the regulatory process remains equally stringent, the FDA has warned against the use of multiple genetic tests with unapproved claims to predict patient response to a specific set of medications.

Prenatal and Newborn Direct-to-Consumer (DTC) Genetic Testing Demand On the Rise, Reliability Remains a Grey Area

Over the period of the last decade, individuals could easily purchase direct-to-consumer (DTC) genetic testing over online transactions to carry out prenatal and newborn genetic testing without the intervention of health professionals. However, companies that offer such tests lack a comprehensive standard data to which the testing results are compared. While the number of companies offering the direct-to-consumer (DTC) genetic testing for newborn screening is increasing, the reliability of their tests remains a grey area owing to the lack of supervision about test content, interpretation and accuracy.

Integration of Artificial Intelligence to Add Value in DTC Genetic Testing

Direct-to-consumer (DTC) genetic testing holds significant importance in the field of personalized medicine. Health data of an individual derived from direct-to-consumer (DTC) genetic testing in the form of genetic sequencing can be linked with other health indications to gain an overall health outlook. Towards this, many direct-to-consumer (DTC) genetic testing companies are engaged in collaborating with pharma companies. Also, with the integration of artificial intelligence (AI) in the medical diagnostic technologies such as direct-to-consumer (DTC) genetic testing, the derived genetic sequencing data becomes more valuable.

Get Discount on Latest Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=4770

Direct-to-Consumer (DTC) Genetic Testing Market Segmentation

Direct-to-consumer (DTC) genetic testing market is segmented on the basis of type, application and technology.

Based on type, the Direct-to-consumer (DTC) genetic testing market is segmented into,

Based on application, the Direct-to-consumer (DTC) genetic testing market is segmented into,

Based on technology, the Direct-to-consumer (DTC) genetic testing market is segmented into,

Go here to see the original:
Direct-to-Consumer (DTC) Genetic Testing Market Analysis On Trends and Need 2028 - Scientect

Data Bridge Market Research has recently published the Global research Report TitledCardiovascular Genetic Testing Market. The study provides an overview of current statistics and future predictions of the Global Cardiovascular Genetic Testing Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry-validated market development data.

Get Free Sample Report + All Related Graphs & Charts: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cardiovascular-genetic-testing-market

The Global Cardiovascular Genetic Testing Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Cardiovascular Genetic Testing market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Cardiovascular Genetic Testing Market in each region. Various methodological tools are used to analyze the growth of the worldwide Cardiovascular Genetic Testing market.

Prominent Key Players Covered in the report:

Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, QIAGEN, Pathway Genomics, Pacific Biosciences of California, Inc, Natera, Inc., Myriad Genetics, Inc., ICON plc, Laboratory Corporation of America Luminex Corporation, IntegraGen., HTG Molecular Diagnostics, Inc. , Genomic Health, Inc., Admera Health, deCODE genetics among other domestic and global players.

Major Regions as Follows:

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

A complete value chain of the global Cardiovascular Genetic Testing market is presented in the research report. It is associated with the review of the downstream and upstream components of the Cardiovascular Genetic Testing Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Cardiovascular Genetic Testing market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Cardiovascular Genetic Testing market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-cardiovascular-genetic-testing-market

How Does This Market Insights Help?

Key Pointers Covered in the Cardiovascular Genetic Testing Market Industry Trends and Forecast to 2026

Reasons to Purchase this Report

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Cardiovascular Genetic Testing Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cardiovascular-genetic-testing-market

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Link:
Cardiovascular Genetic Testing Market Estimated to Expand at a Robust CAGR over 2020 2027 - Scientect

Article In Brief

Scientists identified several cellular abnormalities in the developing cortex from fetal tissues carrying the mutant gene implicated in Huntington's disease. The findings suggest that the disease alters human development at an early age.

Teams of French researchers have found cellular changes that alter cortical development in the brains of human fetuses who carry the mutant huntingtin gene (mHTT) implicated in Huntington's disease (HD).

The finding adds a new wrinkle to the puzzle of HD as many people who carry the mutation can live healthy lives for four decades or longer before the onset of symptoms.

No one knows why, but this is a common thread in other late-onset genetically-driven neurodegenerative conditions like Alzheimer's and Parkinson's disease, the researchers said. And a growing number of researchers believe that it is best to treat people with the HD mutation as early as possible.Now, findings from this study, published online July 16 in Science, beg the question: How early?

The researchers, led by Sandrine Humbert, PhD, research director of INSERM (the French National Institute for Health and Medical Research) and group leader at the Grenoble Institut des Neurosciences, and Alexandra Durr, MD, PhD, professor at Sorbonne University and team leader of the Paris Brain Institute at Pitie-Salptrire Hospital, had access to fetal tissue from families that terminated their pregnancy in the context of a prenatal test. The developing fetus carried the mHTT.

Other mouse and neuroimaging studies with pre-manifest mutation carriers have suggested that the mutation might affect neurodevelopment but this is the first time that scientists have looked to the human fetus to know for sure.

Dr. Durr works with people undergoing genetic testing and counseling for Huntington's disease. Her team was able to collect cortical tissue from four HD mutation carriers when the pregnancies were terminated at around 13-weeks' gestation and tissue from four healthy controls.

This age is an opportune time to assess the tissue, the study authors noted, because at this stage the cortical neurons that project to the striatumthose that become dysfunctional and die during the course of the diseaseare being born from progenitor cells at the ventricular zone.

Thirteen weeks gestation is the time point when you need a lot of cells to be generated, Dr. Humbert explained. At this stage in development cells are massively cycling. The implications for the fetal brain with an HD mutation is that there is a shift to differentiate early and, as a result, you generate fewer neurons, at least at this specific time point during development.

The scientists identified several cellular abnormalities in the developing cortex, including mislocalization of the mutant huntingtin protein and other junction proteins that keep the neuroepithelium sealed. They observed abnormal ciliogenesis and changes in mitosis and cell-cycle progression, which correlated with defects in the balance between renewal and differentiation of progenitors.

In neuroprogenitor cells, this balance is tightly regulated to provide the right amount of neurons along the development of the cortex. Fewer proliferating cells and more progenitors prematurely began to differentiate in the tissues of HD carrierssubtle findings that are changing the landscape of the cortex.

Huntington's definitely has a neurodevelopmental component in addition to a neurodegenerative disease, Dr. Humbert explained. Studies in mice have found similar cellular abnormalities.

These data are supported by similar findings in mice that show mutant HTT impairs neuroprogenitor cell division, migration, and maturation, and that these changes result in a thinner cortex. Additional studies have revealed that early exposure to mutant HTT is enough to trigger signs of HD when the mice grow up. Neuroimaging studies with pre-symptomatic mutation carriers, even children, have shown smaller intracranial volume in HD mutation carriers.

What is also intriguing is that these events occurred even though the fetuses had small pathological expansions39, 40, and 42 repeats that would typically cause an adult onset of HD.

The findings trigger a number of questions: Why aren't there any obvious clinical problems until mid-life? Do these early developmental changes set the stage for symptoms decades down the road? Are other brain cells compensating for the changes and it takes 40-plus years for symptoms to develop?

Dr. Humbert and her colleagues said that the defects we observed likely render the cortico-striatal circuitry more vulnerable to the later dysfunctions characteristic of HD. The path to degeneration is complex, however, and weaves together both pathogenic and compensatory mechanisms.

They cited a recent pair of studies in Neurology by Peg Nopoulos, MD, and her colleagues at the University of Iowa, Carver College of Medicine that looked at children who are HD mutation carriers. They showed initial striatal enlargement with hyper-connectivity between the striatum and the cerebellum. Over time, the striatum decreases and the connections weaken. Although the cerebellar connections initially may help compensate for the abnormally developed striatum, it is the loss of these connections that may ultimately lead to motor abnormalities. Again, it will be decades before any obvious motor signs develop.

Once there are disease-modifying therapies, we know we should treat as early as possible or differently in pre-manifest compared to symptomatic stages of the disease, or it may not be sufficient, said Dr. Humbert.

She said she is now interested in understanding how these early defects contribute to adult pathology, and how their compensation could be regulated during the silent symptom-free period. This should give access to new molecules of interest, either as treatments or biomarkers, she added.

It is a beautiful paper, said Christopher A. Ross, MD, PhD, director of neurobiology and professor of psychiatry and behavioral sciences at Johns Hopkins Medicine. The concept fits with ideas people have had. Their study is groundbreaking.

It's unclear how these cell-cycle abnormalities alter normal development, said Dr. Ross. I have been doing pre-manifest genetic testing for years, and my belief is that asymptomatic people who are far from their predicted onset but test positive are clinically completely normal.

These data are very interesting, said Sarah Tabrizi, MD, PhD, professor of clinical neurology at University College London Institute of Neurology. There has been debate in the HD field regarding the existence of a neurodevelopmental deficit, and evidence is accruing that this may be the case based on differentiating HD induced pluripotent stem cell systems, mouse development, and now these studies of early human development.

We recently found that HD gene carriers ~24 years before predicted disease onset had essentially completely normal brains including normal cortico-striatal connectivity on advanced neuroimaging, apart from a slightly smaller striatum, which we hypothesized resulted in selective vulnerability of the striatum to subsequent neurodegeneration in HD (Lancet Neurology 2020). Importantly, our HD gene carriers performed as well as matched controls on a range of stringent cognitive and motor assessments.

This all suggests that we need to treat as early as possible with disease-modifying therapies to enable us to delay or prevent symptom onset, Dr. Tabrizi said, and means that there is still great potential for therapies to potentially prevent the neurodegeneration occurring if we treat early enough. We need to understand more about the very earliest manifestations of neurodegeneration and then intervene at the optimal stage.

Dr. Ross believes that the brain figures out a workaround of these developmental alterations but agrees that it may leave the brain more vulnerable later in life. He added, These findings are conceptually very important, though not necessarily with immediate implications for patients or those who are asymptomatic but test positive.

He said that this finding represents a paradigm shift that will lead scientists to look for developmental abnormalities in other neurodegenerative diseases.

It is important to emphasize how the Huntington gene (HTT) affects the brain in the context of a lifetime trajectory, added Dr. Nopoulos, the Paul W. Penningroth professor of psychiatry and chair in the department of psychiatry at University of Iowa Carver College of Medicine. This gene is vital for brain development. Our group has shown that HTT drives brain development and that repeats in HTT are beneficial, and the higher the repeat, the higher the IQ. For individuals with repeats in the range of 39-42, like those in the fetal tissue study, HTT likely contributed to the development of a cerebellar-striatal-cortical circuit that was initially advantageous (which is why they are found to be asymptomatic in the Tabrizi study), but later in life, vulnerable to degeneration. Therefore, although the findings in the fetal tissue study are reported as abnormalities, they are more likely to be evidence of differences since the changes are not pathologic until much later in life.

However, she added, everything about HTT is on a spectrumthe classic dose effect of repeats on the age of onset is a good example where greater repeats result in earlier onset. The same is likely true for development.

Human brain development is prolonged, lasting until roughly age 30, she continued. Those with repeats in the low mutant range (36-42) will have a chance for full brain development before the vulnerable cerebellar-striatal-cortical circuit begins to degenerate and disease manifests. However, in those with longer repeats (above 50), the vulnerable brain circuit may begin to degenerate before full brain maturation is complete.

In this range of repeats, the ultimate effect of mHTT on brain development may be detrimental. These considerations are vitally important when considering when to intervene with preventive therapies such as gene knock-down drugs. In those with low mutant repeats, knocking down the gene early in life (before age 30) may be detrimental to brain development, yet in those with high repeats, rescue may need to be much earlier (adolescence).

Drs. Humbert, Durr, Ross, and Nopoulos had no relevant disclosures.

Go here to read the rest:
Huntington's Disease Alters Human Development in the Fetal... : Neurology Today - LWW Journals

Global Prenatal and Newborn Genetic Testing Market: Trends Estimates High Demand by 2026

Prenatal and Newborn Genetic Testing Market report 2020, discusses various factors driving or restraining the market, which will help the future market to grow with promising CAGR. The Prenatal and Newborn Genetic Testing Market research Reports offers an extensive collection of reports on different markets covering crucial details. The report studies the competitive environment of the Prenatal and Newborn Genetic Testing Market is based on company profiles and their efforts on increasing product value and production.

The Global Prenatal and Newborn Genetic Testing market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Prenatal and Newborn Genetic Testing market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The final report will add the analysis of the Impact of Covid-19 in this report Prenatal and Newborn Genetic Testing industry.

Key players in global Prenatal and Newborn Genetic Testing market include: Berry Genomics, Natera, Biorad, Illumina, BGI, Trivitron Healthcare, Sequenom, Laboratory Corporation of America, Ariosa Diagnostics, Qiagen, and Verinata health.

Get a Sample Copy of the [emailprotected] https://www.reportsandmarkets.com/sample-request/global-prenatal-and-newborn-genetic-testing-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=scientect&utm_medium=33

Prenatal and Newborn Genetic Testing Market: Region-wise Outlook

Depending on the geographic region, Prenatal and Newborn Genetic Testing market is divided into seven key regions: North America, Eastern Europe, Latin America, Western Europe, Japan, Asia-Pacific, and the Middle East & Africa. North America dominates the Prenatal and Newborn Genetic Testing market followed by Europe, and Japan owing to high internet penetration, the establishment of key players in the field of the internet such as Google, and Facebook. Asia Pacific, Middle East, and Africa hold huge potential and shows substantial growth in terms of expanding the use of electronic devices, rising innovative technologies, consumer awareness, and expanding telecommunication sector are some of the factors which strengthen the growth of Prenatal and Newborn Genetic Testing market throughout the forecast period.

Questions answered in the report with respect to the regional expanse of the Prenatal and Newborn Genetic Testing market:

The scope of the Report:

The report segments the global Prenatal and Newborn Genetic Testing market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Prenatal and Newborn Genetic Testing market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Reasons to read this Report:

TABLE OF CONTENT:

Chapter 1:Prenatal and Newborn Genetic Testing Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Prenatal and Newborn Genetic Testing Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Prenatal and Newborn Genetic Testing Market Effect Factors Analysis

Chapter 12: GlobalPrenatal and Newborn Genetic Testing Market Forecast to 2026

Complete Report @ https://www.reportsandmarkets.com/sample-request/global-prenatal-and-newborn-genetic-testing-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=scientect&utm_medium=33

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read the original post:
Prenatal and Newborn Genetic Testing Market 2020 2026: Company Profiles, COVID 19 Outbreak, Global Trends, Profit Growth, Industry Segments,...

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Predictive Genetic Testing market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Predictive Genetic Testing market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Predictive Genetic Testing market to assist our clients arrive at beneficial business decisions.

The Predictive Genetic Testing market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Predictive Genetic Testing market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/31204

What pointers are covered in the Predictive Genetic Testing market research study?

The Predictive Genetic Testing market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Predictive Genetic Testing market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Predictive Genetic Testing market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

key players in the predictive genetic testing market. The significant competitive strength of the existing players in the evolving landscape of the global predictive genetic testing market is anticipated to offer new prospect in widening the application of the predictive genetic testing, substantially driving predictive genetic testing market growth. The key manufacturers of the predictive genetic testing are greatly concentrated on the technical edification of the end users to improve consumer outcomes. Furthermore, the adoptions of advanced predictive genetic testing services is expected to create lucrative growth opportunities for the service and third-party market competitors. Growing inclination toward trend in predict is prevention is estimated to offer growth opportunity for Predictive genetic testing market. Selection of treatment regimen with Predictive genetic testing is projected to aid capturing higher share in Predictive genetic testing market.

Geographically, global Predictive genetic testing market is segmented into seven key regions viz. North America, Latin America, Europe, South Asia, East Asia Oceania and Middle East & Africa. North America is prominent region in Predictive genetic testing Market. Advancement in genetic care facilities, higher adoption to lifestyle changes, increase awareness about genetic disease, increase in preventative care and favorable government policies have improved the regulatory scenario for predictive genetic testing devices in north America. Additionally in Asia pacific region considerably higher market growth rate is expected due to constantly rising population and higher incidence of genetic abnormality. Relatively affecting the Predictive genetic testing market.

Some of the major key players competing in the global Predictive genetic testing Market are Myriad Genetics, Inc., Abbott Laboratories, Illumina, Inc., Genesis GeneticsThermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., , Agilent Technologies, F. Hoffmann-La Roche Ltd., Counsyl, Inc., ARUP Laboratories. BGI among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/31204

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Predictive Genetic Testing market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Predictive Genetic Testing market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Predictive Genetic Testing market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/31204

Some of the Major Highlights of TOC covers:

Original post:
Predictive Genetic Testing Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 2029 - The Daily Chronicle

New Jersey, United States,- This detailed market research covers the growth potential of the Direct-To-Consumer (DTC) Genetic Testing Market, which can help stakeholders understand the key trends and prospects of the Direct-To-Consumer (DTC) Genetic Testing market and identify growth opportunities and competitive scenarios. The report also focuses on data from other primary and secondary sources and is analyzed using a variety of tools. This will help investors better understand the growth potential of the market and help investors identify scope and opportunities. This analysis also provides details for each segment of the global Direct-To-Consumer (DTC) Genetic Testing market.

The report was touted as the most recent event hitting the market due to the COVID-19 outbreak. This outbreak brought about a dynamic change in the industry and the overall economic scenario. This report covers the analysis of the impact of the COVID-19 pandemic on market growth and revenue. The report also provides an in-depth analysis of the current and future impacts of the pandemic and post-COVID-19 scenario analysis.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The market is further segmented on the basis of types and end-user applications. The report also provides an estimation of the segment expected to lead the market in the forecast years. Detailed segmentation of the market based on types and applications along with historical data and forecast estimation is offered in the report.

Furthermore, the report provides an extensive analysis of the regional segmentation of the market. The regional analysis covers product development, sales, consumption trends, regional market share, and size in each region. The market analysis segment covers forecast estimation of the market share and size in the key geographical regions.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

Global Direct-to-Consumer (DTC) Genetic Testing Market, By Test Type

Predictive Testing Carrier Testing Nutrigenomics Testing Others

Global Direct-to-Consumer (DTC) Genetic Testing Market, By Technology

Single Nucleotide Polymorphism Chips Whole Genome Sequencing Targeted Analysis

On the basis of regional segmentation, the market is bifurcated into major regions ofNorth America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.The regional analysis further covers country-wise bifurcation of the market and key players.

The research report offered by Verified Market Research provides an updated insight into the global Direct-To-Consumer (DTC) Genetic Testing market. The report covers an in-depth analysis of the key trends and emerging drivers of the market likely to influence industry growth. Additionally, the report covers market characteristics, competitive landscape, market size and growth, regional breakdown, and strategies for this market.

Highlights of the TOC of the Direct-To-Consumer (DTC) Genetic Testing Report:

Overview of the Global Direct-To-Consumer (DTC) Genetic Testing Market

Market competition by Players and Manufacturers

Competitive landscape

Production, revenue estimation by types and applications

Regional analysis

Industry chain analysis

Global Direct-To-Consumer (DTC) Genetic Testing market forecast estimation

This Direct-To-Consumer (DTC) Genetic Testing report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Key Questions Addressed in the Report:

What are the key driving and restraining factors of the global Direct-To-Consumer (DTC) Genetic Testing market?

What is the concentration of the market, and is it fragmented or highly concentrated?

What are the major challenges and risks the companies will have to face in the market?

Which segment and region are expected to dominate the market in the forecast period?

What are the latest and emerging trends of the Direct-To-Consumer (DTC) Genetic Testing market?

What is the expected growth rate of the Direct-To-Consumer (DTC) Genetic Testing market in the forecast period?

What are the strategic business plans and steps were taken by key competitors?

Which product type or application segment is expected to grow at a significant rate during the forecast period?

What are the factors restraining the growth of the Direct-To-Consumer (DTC) Genetic Testing market?

Thank you for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about customization options, and our team will ensure you get the report tailored according to your requirements.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Continued here:
Direct-To-Consumer (DTC) Genetic Testing Market Size and Growth By Leading Vendors, By Types and Application, By End Users and Forecast to 2027 -...

HOUSTON, Aug. 13, 2020 /PRNewswire/ --Baylor Genetics, a clinical diagnostics laboratory known for genetic testing and precision medicine, and Rice University, a private, comprehensive research university located in Houston, Texas, have partnered together to create a first-of-its-kind, total turnkey solution for the university to resume in-person classes for the fall semester despite the COVID-19 pandemic.

"For Baylor Genetics and Rice University, this partnership represents a moon-shot opportunity to benefit students, faculty, and staff," stated Kengo Takishima, President and Chief Executive Officer at Baylor Genetics. "It is imperative families have peace of mind as they send their children to college and we've set an aggressive goal of serving as a blueprint for other academic institutionsand, more broadly, society."

Many universities nationwide have been strongly impacted by the pandemic and have announced changes to the fall semester. One of the major changes is universities going fully online for the semester. Fortunately, Rice has been able to overcome many challenges brought on by COVID-19 thanks to its partnership with Baylor Genetics.

"In terms of learning online, I found that it wasn't that intuitive and effective for my own learning style. In addition to that, it is my senior year and I wanted to get one last taste of the community that I have come to grow and love here," said Victor Nguyen, a senior at Rice University, in an interviewreleased by the university. "Being on campus again feels a little bit more of what we are used to, even though we live in a new reality. It's closer to normal so it's exactly what we were hoping for."

This partnership entails Baylor Genetics providing support for temperature checks, on-campus sample collection and transport logistics, processing of samples, and customized results reporting for individuals via email. Nearly 60,000 screening tests will be performed by Baylor Genetics with a turnaround time of 48 hours or less.

In addition to large-scale surveillance testing, the partnership includes population management reporting. This custom reporting system delivers population data to assist policymakers at Rice with managing the campus community and by aiding in intelligent decision making.

"Testing by itself is not enough," said Kevin Kirby, Rice University's Vice President for Administration."What matters is how we use that information to act quickly to isolate, treat, contact trace, and quarantine those affected. A systematic approach is the best practice for creating an environment that will mitigate the spread of COVID-19."

In addition, data tracking will provide the university with specific trends and infection rates on buildings, facilities, and housing throughout the campus. This innovative approach is part of Rice's strategy to prevent cross-contamination and ensure the safety of its faculty, students, and staff. There are plans to extend the partnership with symptomatic testing in the near future.

"This opportunity is a chance to demonstrate that we can operate safely in such a difficult time," said Chad Shaw, Ph.D., Sr. Director of the Baylor Genetics Innovation Lab, Adjunct Professor of Statistics at Rice University, and Professor in the Department of Molecular and Human Genetics at Baylor College of Medicine, "As a Houstonian and a member of both the Baylor and Rice faculty, I am excited by the opportunity to serve my community to find a thoughtful and creative way to overcome the COVID challenge. It takes commitment, grit, and a team effort."

The program began the week of Aug. 3 with college staff, graduate students, and orientation coordinators. For students, testing is broken down into three phases and will begin Aug. 15. There will be no charge to faculty, studentsor staff for the on-campus testing.

For members of the Rice community that are confirmed positive for the coronavirus (SARS-CoV-2), Rice will follow the Centers for Disease Control and Prevention contact-tracing protocols to identify others who have had significant contact with those tested positive.

Baylor Genetics' test for COVID-19 has one of the highest sensitivity (true positive rate) and specificity (true negative rate) rates for identifying active coronavirus infection. All precautions, policies, and guidelines have been put in place with one goal in mind continue education in the safest, most effective way possible.

Media Contact:Jamie LimEmail: [emailprotected]

Related Images

on-campus-collection-site-at-rice.jpg On-campus collection site at Rice University

Related Links

COVID-19 Testing at Baylor Genetics

Return to Rice

SOURCE Baylor Genetics

View post:
Baylor Genetics and Rice University Form COVID-19 Screening Partnership for the Fall Semester; Partnership Aims for 'Moon-Shot' 48-Hours-or-Less...

Dublin, Aug. 14, 2020 (GLOBE NEWSWIRE) -- The "DTC (Direct to Consumer) DNA Test Kits Market - Growth, Trends, and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

The Global DTC DNA Test Kits Market is anticipated to grow with a CAGR of nearly 24% during the forecast period.

The major factors attributing to the growth of this market are increasing demand for paternity testing, rising prevalence of hereditary diseases, and rise in interest of consumers & physicians in DTC kits & consequent rise in sales of DNA test kits.

Furthermore, the growing number of laboratories researching the DNA kits for gynecological purposes is also a major factor that drives the market growth. For instance, the National Congenital Anomaly and Rare Disease Registration Service has stated that around 3 to 6% of babies worldwide are born with a congenital anomaly every year, this increases the need for the prenatal testing for anomalies. The difficulty in understanding the results of the kits and very less information about the companies selling the kits are restraining the growth of the market.

Furthermore the market is largely penetrating towards new research fields of medicine and healthcare as such the innovation of probes for preimplantation, prenatal, and postnatal genetic testing research drives the overall market growth.

Key Market Trends

Demand for Ancestry Testing is Expected to Increase During the Forecast Period

An ancestry test is a DTC DNA-based test that reads specific locations of a subject's genome, to find or validate ancestral hereditary relationships or to evaluate the ethnic combination of an individual. The increasing number of people who are interested in knowing their ancestors and family tree increases the demand for DTC DNA test kits, especially in developing countries.

The increasing number of companies such as 23andMe are found to offer various DNA kits that are helpful in ancestry testing. Developed countries are also witnessing the high demand for such products as awareness about such technologies is higher.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall DTC DNA test kits market, throughout the forecast period. The growth is due to factors such as the growing prevalence of congenital anomalies and increasing government initiatives for genetic diagnosis. In the North America region, the United States holds the largest market share due to factors such as high disposable income, and easy acceptance of such kits in the country is expected to increase the demand in this region.

However, Asia Pacific is anticipated to be the fastest-growing market due to the increasing awareness programs and developments undertaken by government bodies to accelerate genetic research in Asian countries. The Asia Pacific will proliferate at a speedy rate due to rapid technological updation in the healthcare sector.

Competitive Landscape

The market studied is moderately competitive and consists of few major players. Growing biotech industry is augmenting the rise in new entrants in this market. It is belived that there will be penetration of the few small to mid sized compaies in this market.

Key Topics Covered

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Increasing Demand for Paternity Testing4.2.2 Increasing Number of Hereditary Diseases4.2.3 Rise in Interest of Consumers & Physicians in DTC Kits & Consequent Rise in Sales of DNA Test Kits4.3 Market Restraints4.3.1 Lack of Awareness and Proper Genetic Counselling4.3.2 Regulatory Challenges Pertaining to the Use of DTC Genetic Tests4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION5.1 By Sample Type5.1.1 Saliva5.1.2 Cheek Swab5.2 By Application5.2.1 Genetic Relatedness5.2.2 Health & Fitness5.2.3 Ancestry Testing5.2.4 Other Applications5.3 Geography5.3.1 North America5.3.2 Europe5.3.3 Asia-Pacific5.3.4 Middle-East & Africa5.3.5 South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Ancestry.com LLC6.1.2 23andMe6.1.3 MyHeritage Ltd.6.1.4 Gene by Gene6.1.5 Living DNA Ltd.6.1.6 National Geographic Partners, LLC6.1.7 Helix OpCo, LLC6.1.8 Veritas6.1.9 Futura Genetics6.1.10 Illumina, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/mvzrhk

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read more from the original source:
Global DTC DNA Test Kits Industry Outlook, 2025 - Demand for Ancestry Testing Expected to Increase - GlobeNewswire

What to Know About Your Ovarian Cancer Genes

Most of the time, ovarian cancer happens randomly. Genetic changes occur spontaneously within cells that make them turn cancerous. But a smaller percentage of women with ovarian cancer have inherited a genetic predisposition that make them more likely to develop this cancer. Testing for these inherited gene changes can help better target the treatment women receive, and inform the health decisions their family members make.

The most important thing for a woman whos been newly diagnosed with ovarian cancer or tubal cancer to know is that its very important to get genetic testing, because almost 25% of women who have a new diagnosis of ovarian cancer will be found to have a genetic mutation, explains Dr. Karen Zempolich, gynecologic oncologist at St. Marks Hospital in Salt Lake City.

Many women have heard of BRCA mutations, Dr. Zempolich says. Normally, the BRCA1 and BRCA2 genes protect you against cancer by helping your cells repair broken DNA that can turn the cells cancerous. But when these genes are changed, or mutated, cells can no longer fix themselves.

People who inherit the BRCA gene mutations are more likely to get not only ovarian cancer, but also breast cancer. There are also many other genes that contribute to ovarian cancer, which genetic testing can reveal. Getting tested can also help your doctor make more informed decisions about your treatment.

Learning that you have a genetic mutation is not only important for determining your risk of ovarian and breast cancers, but it also gives your doctor the chance to use a whole new set of medicines against ovarian cancer that could improve your survival, Dr. Zempolich says.

Normally when a strand of DNA is damaged, enzymes called PARPs rush in to fix the damage. New medicines called PARP inhibitors help counteract that protective mechanism, she says. Cancer cells cant finish the repair process, so they stop growing and spreading.

PARP inhibitor drugs work best in women who have BRCA1 and BRCA2 mutations, because the cancer cells are already at a loss to repair themselves. Taking PARP inhibitors can extend the time before a womans cancer comes back, and possibly prolong her survival.

If a woman has a BRCA or other gene mutation, there may be a good chance that her family members carry it too, since these mutations are inherited. Families with BRCA mutations and multiple cases of ovarian and/or breast cancers are said to have a cancer predisposition syndrome called Hereditary Breast and Ovarian Cancer Syndrome (HBOC).

Knowing their genetic status can inform important health decisions for everyone in the family. Women who test positive for genes linked to ovarian cancer may want to consider having prophylactic surgery, removing their ovaries and fallopian tubes to prevent cancer from developing in the future.

Its important for men to also consider their genetic risks. The gene mutations that are linked to ovarian cancer also increase the risk for breast cancer (which men can get too), as well as for colon cancer, melanoma, and upper GI tract cancers, Dr. Zempolich says.

Once youve been diagnosed with ovarian cancer, your doctor will likely send you for genetic testing. Most insurance companies should cover the cost, Dr. Zempolich says.

If your doctor isnt sure whether you have a familial ovarian cancer syndrome, you can meet with a genetic counselor to determine what, if any, testing you need. The counselor can help you decide whether or not thats an important part of your journey with this cancer, she adds.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Karen Zempolich is a gynecologic oncologist at St. Mark's Hospital in Salt Lake City, Utah. She specializesin complex pelvic and oncologic surgery, laparoscopic surgery, and fertility-sparing treatment of early gynecologic cancers. Read More

The most important thing for a woman whos been newly diagnosed with ovarian cancer or tubal cancer to know is that its very important to get genetic testing, because almost 25% of women who have a new diagnosis of ovarian cancer will be found to have a genetic mutation, explains Dr. Karen Zempolich, gynecologic oncologist at St. Marks Hospital in Salt Lake City.

People who inherit the BRCA gene mutations are more likely to get not only ovarian cancer, but also breast cancer. There are also many other genes that contribute to ovarian cancer, which genetic testing can reveal. Getting tested can also help your doctor make more informed decisions about your treatment.

Learning that you have a genetic mutation is not only important for determining your risk of ovarian and breast cancers, but it also gives your doctor the chance to use a whole new set of medicines against ovarian cancer that could improve your survival, Dr. Zempolich says.

Normally when a strand of DNA is damaged, enzymes called PARPs rush in to fix the damage. New medicines called PARP inhibitors help counteract that protective mechanism, she says. Cancer cells cant finish the repair process, so they stop growing and spreading.

PARP inhibitor drugs work best in women who have BRCA1 and BRCA2 mutations, because the cancer cells are already at a loss to repair themselves. Taking PARP inhibitors can extend the time before a womans cancer comes back, and possibly prolong her survival.

If a woman has a BRCA or other gene mutation, there may be a good chance that her family members carry it too, since these mutations are inherited. Families with BRCA mutations and multiple cases of ovarian and/or breast cancers are said to have a cancer predisposition syndrome called Hereditary Breast and Ovarian Cancer Syndrome (HBOC).

Knowing their genetic status can inform important health decisions for everyone in the family. Women who test positive for genes linked to ovarian cancer may want to consider having prophylactic surgery, removing their ovaries and fallopian tubes to prevent cancer from developing in the future.

Its important for men to also consider their genetic risks. The gene mutations that are linked to ovarian cancer also increase the risk for breast cancer (which men can get too), as well as for colon cancer, melanoma, and upper GI tract cancers, Dr. Zempolich says.

Once youve been diagnosed with ovarian cancer, your doctor will likely send you for genetic testing. Most insurance companies should cover the cost, Dr. Zempolich says.

If your doctor isnt sure whether you have a familial ovarian cancer syndrome, you can meet with a genetic counselor to determine what, if any, testing you need. The counselor can help you decide whether or not thats an important part of your journey with this cancer, she adds.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Karen Zempolich is a gynecologic oncologist at St. Mark's Hospital in Salt Lake City, Utah. She specializesin complex pelvic and oncologic surgery, laparoscopic surgery, and fertility-sparing treatment of early gynecologic cancers. Read More

Here is the original post:
How Genes Can Shape A Womans Ovarian Cancer Care, And Her Familys Medical Decisions - SurvivorNet

New Jersey, United States,- Verified Market Researchhas recently published an extensive report on the Direct-To-Consumer (DTC) Genetic Testing Market to its ever-expanding research database. The report provides an in-depth analysis of the market size, growth, and share of the Direct-To-Consumer (DTC) Genetic Testing Market and the leading companies associated with it. The report also discusses technologies, product developments, key trends, market drivers and restraints, challenges, and opportunities. It provides an accurate forecast until 2027. The research report is examined and validated by industry professionals and experts.

The report also explores the impact of the COVID-19 pandemic on the segments of the Direct-To-Consumer (DTC) Genetic Testing market and its global scenario. The report analyzes the changing dynamics of the market owing to the pandemic and subsequent regulatory policies and social restrictions. The report also analyses the present and future impact of the pandemic and provides an insight into the post-COVID-19 scenario of the market.

Global Direct-to-Consumer (DTC) Genetic Testing Market was valued at USD 789.92 Million in 2018 and is projected to reach USD 2,361.12 Billion by 2026, growing at a CAGR of 14.59% from 2019 to 2026.

The report further studies potential alliances such as mergers, acquisitions, joint ventures, product launches, collaborations, and partnerships of the key players and new entrants. The report also studies any development in products, R&D advancements, manufacturing updates, and product research undertaken by the companies.

Leading Key players of Direct-To-Consumer (DTC) Genetic Testing Market are:

Competitive Landscape of the Direct-To-Consumer (DTC) Genetic Testing Market:

The market for the Direct-To-Consumer (DTC) Genetic Testing industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

Global Direct-to-Consumer (DTC) Genetic Testing Market, By Test Type

Predictive Testing Carrier Testing Nutrigenomics Testing Others

Global Direct-to-Consumer (DTC) Genetic Testing Market, By Technology

Single Nucleotide Polymorphism Chips Whole Genome Sequencing Targeted Analysis

Regional Analysis of Direct-To-Consumer (DTC) Genetic Testing Market:

A brief overview of the regional landscape:

From a geographical perspective, the Direct-To-Consumer (DTC) Genetic Testing Market is partitioned into

North Americao U.S.o Canadao MexicoEuropeo Germanyo UKo Franceo Rest of EuropeAsia Pacifico Chinao Japano Indiao Rest of Asia PacificRest of the World

Key coverage of the report:

Other important inclusions in Direct-To-Consumer (DTC) Genetic Testing Market:

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

View original post here:
Direct-To-Consumer (DTC) Genetic Testing Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line

The research report on the Direct-to-consumer Genetic Testing market leverages iterative and comprehensive research methodology to deliver insights regarding the current market scenario over the study timeframe. The report dives deep into the development trends that will influence the behavior of the Direct-to-consumer Genetic Testing + market in the forthcoming years. Moreover, other key pointers such as the regional characteristics and policies governing the industry are highlighted in the research. Apart from this, the study incorporates the impact of the COVID-19 pandemic on the revenue share and annual growth rate of the industry.

A new report on Direct-to-consumer Genetic Testing market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising the current and future trends defining the dynamics of this industry vertical, this report also incorporates the regional landscape of Direct-to-consumer Genetic Testing market in tandem with its competitive terrain.

The market analysis showcases the vast research on the product terrain which is inclusive of the advantages and disadvantages of the products developed by the various manufacturers. Besides this, an investigation of the evolution of the competitive dynamics along with details pertaining to raw material supply chain and downstream buyers are presented in the report.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/169156

A gist of the competitive landscape of the Direct-to-consumer Genetic Testing market:

An outline of the regional scope of the Direct-to-consumer Genetic Testing market:

Global Direct-to-consumer Genetic Testing Market Segmentation:This market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level.

Additional takeaways from the Direct-to-consumer Genetic Testing market report:

Highlights points of Direct-to-consumer Genetic Testing Industry:

Key questions answered in the report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/169156

More here:
Direct-to-consumer Genetic Testing Market Research Growth by Manufacturers, Regions, Type and Application, Forecast Analysis to 2025 - Express Journal

Many countries have never experienced a major oil spill. The critical steps taken in the early days ... [+] can make all the difference to the cleanup that may be needed for decades to come.

Major oil spills, like what happened on the Indian Ocean Island of Mauritius last Thursday, are unfortunately more common than they should be.

Years of forcing the global shipping industry to increase sustainability and safety standards have not yielded sufficient results, as international shipping continues to lag behind on climate change commitments.

This has placed many smaller nations, without the resources to handle a major oil incident, woefully unprepared to deal with the complexity and magnitude of how to handle major industrial oil spill, as Mauritius found to its cost last week. As an aging and abandoned large crude oil tanker off the coast of Yemen is also at risk of spilling across the entire Red Sea, causing the US Secretary of State to issue an alert, what steps do countries have to take if a major oil spill hits their shores for the first time?

What happens when there is an oil spill and what steps should a country take, particularly if theyve never experienced such an event.

It all eventually boils down to two questions.

A bi-partisan US Congress hosts a hearing in 2007 on the Cosco Busan Heavy Fuel Oil spill in San ... [+] Francisco Bay during the Independent Accident Investigation as well as Natural Resources Damage Assessment - key tools to conducting any meaningful inquiry.

After all is said and done, oil cleanup operations come down to two questions: who pays, and how much do they pay. Some key early decisions could mean an order of magnitude (ten times) difference in any payout. This is critical to know.

All major shipping companies pay into catastrophic risk insurance. Ultimately, any funds for restoration of habitats will come from this pooled risk insurance that has pockets of billions of dollars. As a comparison, compensation for the Deepwater Horizon oil spill in 2010, which had a robust scientific assessment behind it, was $20 billion, for Exxon Valdez oil spill in 1989 it was $5 billion (over $10.5 billion in todays prices). If bilateral settlement terms for what is a reasonable cost of cleanup cannot be reached, this will often go to arbitration. This is a well understood process.

At such arbitration, the quality of the data collected in the early days of the incident will make all the difference in the decision of the magnitude of payout made.

Here are the five critical steps that any country experiencing an oil spill must take in the immediate days following a crisis.

Salvage teams work on containment of oil as well as ensuring the stability of the vessel during the ... [+] initial Containment phase.

There are two aspects to this: containing the oil spill itself, and salvaging the vessel. This often entails two different sets of experts for each challenge.

A key group of international technical experts in suggesting effective spill response techniques to a maritime incident is ITOPF. They are usually activated by a vessels owner and insurer. They may organize a spill response team, such as Oil Spill Response Limited, which are the largest international industry-funded cooperative that exists to respond to oil spills wherever in the world they may occur, by providing preparedness, response and intervention services. They are wholly owned by most of the environmentally responsible oil and gas companies, who employ 275 people across 12 locations around the world. They also respond to spills for non-members, subject to a set of pre-set fees.

They are the teams who advise and lead on the initial operational details of containing the oil spill, including at distances far from the actual accident site itself.

In cases where vessels have been structurally impacted, the experts are typically the large, global, salvage companies who are appointed by the ships owners and insurers.

Proper scientific protocols must be followed to ensure any evidence collected can be admitted into ... [+] the investigation, for example using gloves, and correctly documenting and storing samples following an approved chain of custody.

Whilst in many countries there is often the initial shock, confusion and coordination challenges in the immediate aftermath of a spill, the samples collected in the immediate days following a spill (and continually in the following days and weeks), will be the biggest determination of any cleanup compensation payout.

No resource should be spared collecting these samples using the right scientific protocols that would be admissible in any arbitration. The pay off from extensive and well cataloged samples could mean the difference of a payout that is orders of magnitude (ten times) greater, and would justify any investment in the collection team and robust scientific protocols that could be admissible in any arbitration.

Once this window is missed, it may be too late to see the full extent of the damage caused, as lessons from the quality of sampling around the Cosco Busan show.

Biological samples (such as coral, fish, mangrove tissue) can reveal certain bio-markers of where the pollution may have traveled that is invisible to the naked eye or satellite evidence. To obtain these indicators, specimens need to be genetically tested using specialist genomic equipment that is widely available in the US and Europe.

SAR Satellite imagery reveals that the oil spill had drifted as far as Ile aux Cerfs by Tuesday ... [+] August 11 2020., 14 miles North of the crash site due to the heavy winds along the East Coast (this is a major kite surfing zone). This type of data may not be visible to the naked eye, but can help track the potential genetic marking impact of the spill.

Often such equipment is not present in the location of the spill and there is a several week delay for this to arrive (especially given Covid-19). However, this does not mean samples should not be collected daily from specific locations under specific protocols. These samples can be frozen and tested many weeks or months later when the right equipment arrives.

Incidentally, due to Mauritius strong response to Covid-19 (there are no local cases), many PCR kits are currently available which may end up being one of the most powerful tools in the oil spill response. That, combined with armies of specially trained volunteers from the tourism and fishing community who know the area, could give a strong advantage for a unified a national response.

The US Agency responsible for environmental impact assessments after a major oil spill, NOAA, offers ... [+] guidance to countries on how to best conduct such assessments, including the document templates to accurately log all specimens and samples that are collected.

What is most important for samples to be admitted in any arbitration settlement is the strict cataloging of the chain of custody and storage of the samples. The importance of this cannot be emphasized enough. Many cases have fallen apart when it was alleged that samples could have been tampered with.

Fortunately, Mauritius has a large and secure tuna industry and aquaculture facilities with refrigeration and security capacity that should address these concerns.

The documentation and protocols can be printed off from existing documentation, such as on Page 23 of NOAAs guide to Heavy Fuel Oil spills. Often a swift training is required for all collecting officers. Given the large local fishing and tourism sector around the crash location, Mauritius has the opportunity to secure and freeze a much more compelling set of baseline data than many other countries. Especially given how well studied and monitored the wildlife sanctuaries around the crash site were.

When major oil spill or mining accidents occur, there is often anger and confusion. Whilst there is ... [+] a process to determine what happened, a completely separate and de-politicized process should be run in parallel to get the world's best, independent scientific experts to conduct an extensive Natural Resource Damage Assessment. Image of protests at Brazilian Mining Giant, Vale, following a mining accident in 2019.

There is often a fog of war after a major oil spill, particularly where this happens in a country for the first time. It took two major oil spills (1969 Santa Barbara, California and 1989 Exxon Valdez) for the US to fully have its standard operating protocols and laws in place, so they could better handle the Cosco Busan in San Francisco Bay in 2007.

In most countries, there is often inter-departmental challenges. In the US, following major oil spills, the Port Authorities are often at odds with the Environmental Agencies (EPA and NOAA). However, in the most effective cases, they are put under the umbrella of the US Department of Justice to ensure a coordinated response with sufficient and fast-tracked funds, to ensure the best possible outcome for the citizens of the affected area.

Whilst there may initially be trade-offs between who pays for sample collections, scientific information, and other baseline impact studies, resourcing should be agreed in a unified way. In the United States, there are often well established established Accident Investigation Boards for major events that look into the forensics of the incidents and lessons learned. Such processes into the causes of what happened should be handled separately from preparing a strong and independent Natural Resource Damage Assessment case for compensation from any polluter.

Countries should engage their own, independent oil spill experts to assess the damage to the Natural ... [+] Resources. This team will be responsible for independently deciding sample location and overseeing the sample collection and storage process.

These should be separate from those provided by the polluting company, the insurer or any host nation associated with a polluter

This is critical. Given the magnitude in any payout, not all international experts are incentivized to offer objective advice. In many cases, it may be more prudent for the insurer to have a counter-narrative to diminish the potential impact (e.g., describing an environment that was already in decline, tourism was impacted by Covid-19 or that multiple factors were to blame, rather than what the insurer is responsible for).

Where a country has its own set of independent experts who have gone through major oil spills before, these countries are always more effectively prepared with a stronger, unified narrative. Given that settlements are often in the hundreds of millions of dollars and even billions of dollars, there are very high stakes here to have the right, independent experts on the side of the country and citizens who have been impacted.

A world class science team will ensure appropriate security and storage of all samples from as wide ... [+] a location as possible, to be admissible in any Natural Resources Damages Assessment

The centerpiece of any claim will come down to the credibility of the science presented. This will be determined by the quality of the samples and data collected (including how strictly scientific protocols were carried out and the extensiveness of the tests), as well as the quality of the experts engaged.

Often, a polluter or host nation would offer to pay for a scientific team. This could lead to sub-optimal outcomes for the host nation. Not all scientists are equal, and each may use different approaches to reduce their assessment of impact.

One example that has been seen in many places is for a scientist to cut fish into slices to visually look for the presence of oil as the main indicator. Whilst this makes for compelling media images, this does not give robust scientific information. When a fish takes in oil, it is akin to a human drinking alcohol. The liver de-toxifies (reduces the toxicity) of the alcohol. The only way to accurately assess the impact of an oil spill is through advanced genetic testing.

There is a specific gene that is sought for in genetic testing and that is the famous CYP1A gene (part of the family of CYP enzymes). This is a critical indicator in response to oil spills. This is a well known bio-marker that indicates the fish defense mechanisms have been activated against the pollution. If more of this enzyme is made, that may be an indicator that the fish trying to detoxify itself, as admissible evidence of stress due to the oil spill. This is the true measure to understand the impact of an oil spill (not visual inspection of a slice of fish), which reveals that oil spills are often the invisible killer to marine life. These bio-markers can easily be detected using PCR tests, that are commonly being used for Covid-19 testing.

The output from DNA results will look like a series of lines. Experts will know how to read these ... [+] and search for the CYP1A class of gene that indicates stress from oil pollution, and can be detected from PCR Kits.

Hence it is important that any country impacted agree swiftly on an international scientific team from an internationally respected university who can work with local scientists to jointly frame the right questions and focus immediately on collecting the right samples. With Exxon Valdez in Alaska, only a certain set of species population needed to be monitored. With more biodiverse areas, experts in animal diseases from corals, mangroves, birds, turtles, insects, dolphins, whales, crustaceans, plants, flowers and trees would need to be engaged to know which indicators to start searching for. Some of the worlds leading scientists who worked on behalf of the communities that secured the $20 billion settlement from BP from the Deepwater Horizon well blowout, are at Stanford Universitys Marine Hopkins Laboratory in California. They also happen to have some of the worlds deepest expertise in the Indian Ocean, covering coral reefs, fish and other rare marine life found only in the Indian Ocean.

If the funding party (the polluter or their sponsoring nation) does not agree to a highly credible, world class scientific team from a separate country, it is often prudent for the host Government to pay for this scientific expertise themselves and be reimbursed later during any settlement. These costs may be as high as $3 million initially for the full range of scientific logging, right equipment, and expertise that a world class scientific team can oversee and evaluate the samples being collected, working and training local scientists to build capacity long after the international scientists have left.

Bearing in mind that the Cosco Busans settlement was $44m for a spill that was in the heavily industrial San Francisco Bay three and a half times smaller than the Wakashio in Mauritius and significantly smaller than the risk from theSafer tanker off the coast of Yemen and the environmentally sensitive Red Sea with some of the last remaining Pristine Corals, the investment in the right internationally renown scientific team early on could immensely strengthen any case during arbitration.

Link:
The Critical First Five Steps Every Country Should Take When Responding To A Major Oil Spill - Forbes

LOS ANGELES, United States: QY Research has recently published a report, titled Global Breast Cancer Predictive Genetic Testing Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Breast Cancer Predictive Genetic Testing market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Breast Cancer Predictive Genetic Testing market include: , Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae Breast Cancer Predictive Genetic Testing

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1967056/global-breast-cancer-predictive-genetic-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Breast Cancer Predictive Genetic Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Breast Cancer Predictive Genetic Testing Market Segment By Type:

High Penetrant GenesIntermediate Penetrant GenesLow Penetrant Genes Breast Cancer Predictive Genetic Testing

Global Breast Cancer Predictive Genetic Testing Market Segment By Application:

HospitalsClinicsOther

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Breast Cancer Predictive Genetic Testing market.

Key companies operating in the global Breast Cancer Predictive Genetic Testing market include , Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae Breast Cancer Predictive Genetic Testing

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1967056/global-breast-cancer-predictive-genetic-testing-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Breast Cancer Predictive Genetic Testing Revenue1.4 Market by Type1.4.1 Global Breast Cancer Predictive Genetic Testing Market Size Growth Rate by Type: 2020 VS 20261.4.2 High Penetrant Genes1.4.3 Intermediate Penetrant Genes1.4.4 Low Penetrant Genes1.5 Market by Application1.5.1 Global Breast Cancer Predictive Genetic Testing Market Share by Application: 2020 VS 20261.5.2 Hospitals1.5.3 Clinics1.5.4 Other1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global Breast Cancer Predictive Genetic Testing Market Perspective (2015-2026)2.2 Global Breast Cancer Predictive Genetic Testing Growth Trends by Regions2.2.1 Breast Cancer Predictive Genetic Testing Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Breast Cancer Predictive Genetic Testing Historic Market Share by Regions (2015-2020)2.2.3 Breast Cancer Predictive Genetic Testing Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Breast Cancer Predictive Genetic Testing Market Growth Strategy2.3.6 Primary Interviews with Key Breast Cancer Predictive Genetic Testing Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Breast Cancer Predictive Genetic Testing Players by Market Size3.1.1 Global Top Breast Cancer Predictive Genetic Testing Players by Revenue (2015-2020)3.1.2 Global Breast Cancer Predictive Genetic Testing Revenue Market Share by Players (2015-2020)3.1.3 Global Breast Cancer Predictive Genetic Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Breast Cancer Predictive Genetic Testing Market Concentration Ratio3.2.1 Global Breast Cancer Predictive Genetic Testing Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Breast Cancer Predictive Genetic Testing Revenue in 20193.3 Breast Cancer Predictive Genetic Testing Key Players Head office and Area Served3.4 Key Players Breast Cancer Predictive Genetic Testing Product Solution and Service3.5 Date of Enter into Breast Cancer Predictive Genetic Testing Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Breast Cancer Predictive Genetic Testing Historic Market Size by Type (2015-2020)4.2 Global Breast Cancer Predictive Genetic Testing Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Breast Cancer Predictive Genetic Testing Market Size by Application (2015-2020)5.2 Global Breast Cancer Predictive Genetic Testing Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Breast Cancer Predictive Genetic Testing Market Size (2015-2020)6.2 Breast Cancer Predictive Genetic Testing Key Players in North America (2019-2020)6.3 North America Breast Cancer Predictive Genetic Testing Market Size by Type (2015-2020)6.4 North America Breast Cancer Predictive Genetic Testing Market Size by Application (2015-2020) 7 Europe7.1 Europe Breast Cancer Predictive Genetic Testing Market Size (2015-2020)7.2 Breast Cancer Predictive Genetic Testing Key Players in Europe (2019-2020)7.3 Europe Breast Cancer Predictive Genetic Testing Market Size by Type (2015-2020)7.4 Europe Breast Cancer Predictive Genetic Testing Market Size by Application (2015-2020) 8 China8.1 China Breast Cancer Predictive Genetic Testing Market Size (2015-2020)8.2 Breast Cancer Predictive Genetic Testing Key Players in China (2019-2020)8.3 China Breast Cancer Predictive Genetic Testing Market Size by Type (2015-2020)8.4 China Breast Cancer Predictive Genetic Testing Market Size by Application (2015-2020) 9 Japan9.1 Japan Breast Cancer Predictive Genetic Testing Market Size (2015-2020)9.2 Breast Cancer Predictive Genetic Testing Key Players in Japan (2019-2020)9.3 Japan Breast Cancer Predictive Genetic Testing Market Size by Type (2015-2020)9.4 Japan Breast Cancer Predictive Genetic Testing Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Breast Cancer Predictive Genetic Testing Market Size (2015-2020)10.2 Breast Cancer Predictive Genetic Testing Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Breast Cancer Predictive Genetic Testing Market Size by Type (2015-2020)10.4 Southeast Asia Breast Cancer Predictive Genetic Testing Market Size by Application (2015-2020) 11 India11.1 India Breast Cancer Predictive Genetic Testing Market Size (2015-2020)11.2 Breast Cancer Predictive Genetic Testing Key Players in India (2019-2020)11.3 India Breast Cancer Predictive Genetic Testing Market Size by Type (2015-2020)11.4 India Breast Cancer Predictive Genetic Testing Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Breast Cancer Predictive Genetic Testing Market Size (2015-2020)12.2 Breast Cancer Predictive Genetic Testing Key Players in Central & South America (2019-2020)12.3 Central & South America Breast Cancer Predictive Genetic Testing Market Size by Type (2015-2020)12.4 Central & South America Breast Cancer Predictive Genetic Testing Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Roche13.1.1 Roche Company Details13.1.2 Roche Business Overview13.1.3 Roche Breast Cancer Predictive Genetic Testing Introduction13.1.4 Roche Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020))13.1.5 Roche Recent Development13.2 Thermo Fisher Scientific13.2.1 Thermo Fisher Scientific Company Details13.2.2 Thermo Fisher Scientific Business Overview13.2.3 Thermo Fisher Scientific Breast Cancer Predictive Genetic Testing Introduction13.2.4 Thermo Fisher Scientific Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020)13.2.5 Thermo Fisher Scientific Recent Development13.3 PerkinElmer13.3.1 PerkinElmer Company Details13.3.2 PerkinElmer Business Overview13.3.3 PerkinElmer Breast Cancer Predictive Genetic Testing Introduction13.3.4 PerkinElmer Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020)13.3.5 PerkinElmer Recent Development13.4 Quest Diagnostics13.4.1 Quest Diagnostics Company Details13.4.2 Quest Diagnostics Business Overview13.4.3 Quest Diagnostics Breast Cancer Predictive Genetic Testing Introduction13.4.4 Quest Diagnostics Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020)13.4.5 Quest Diagnostics Recent Development13.5 Myriad Genetics13.5.1 Myriad Genetics Company Details13.5.2 Myriad Genetics Business Overview13.5.3 Myriad Genetics Breast Cancer Predictive Genetic Testing Introduction13.5.4 Myriad Genetics Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020)13.5.5 Myriad Genetics Recent Development13.6 Iverson Genetics13.6.1 Iverson Genetics Company Details13.6.2 Iverson Genetics Business Overview13.6.3 Iverson Genetics Breast Cancer Predictive Genetic Testing Introduction13.6.4 Iverson Genetics Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020)13.6.5 Iverson Genetics Recent Development13.7 Cancer Genetics13.7.1 Cancer Genetics Company Details13.7.2 Cancer Genetics Business Overview13.7.3 Cancer Genetics Breast Cancer Predictive Genetic Testing Introduction13.7.4 Cancer Genetics Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020)13.7.5 Cancer Genetics Recent Development13.8 OncoCyte Corporation13.8.1 OncoCyte Corporation Company Details13.8.2 OncoCyte Corporation Business Overview13.8.3 OncoCyte Corporation Breast Cancer Predictive Genetic Testing Introduction13.8.4 OncoCyte Corporation Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020)13.8.5 OncoCyte Corporation Recent Development13.9 NeoGenomics13.9.1 NeoGenomics Company Details13.9.2 NeoGenomics Business Overview13.9.3 NeoGenomics Breast Cancer Predictive Genetic Testing Introduction13.9.4 NeoGenomics Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020)13.9.5 NeoGenomics Recent Development13.10 Invitae13.10.1 Invitae Company Details13.10.2 Invitae Business Overview13.10.3 Invitae Breast Cancer Predictive Genetic Testing Introduction13.10.4 Invitae Revenue in Breast Cancer Predictive Genetic Testing Business (2015-2020)13.10.5 Invitae Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:
Breast Cancer Predictive Genetic Testing Market 2020-2026: Key Vendor Landscape By Regional Output, Demand By Countries And Future Growth|Roche,...

News Release

Wednesday, August 12, 2020

According to a new study, mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment.

The study was led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. The findings were published August 12, 2020, in the New England Journal of Medicine.

Reduced tobacco consumption in the U.S. has been associated with a progressive decrease in lung cancer deaths that started around 1990 in men and around 2000 in women.Until now, however, we have not known whether newer treatments might contribute to some of the recent improvement, said Douglas R. Lowy, M.D., NCI deputy director and co-author of this study. This analysis shows for the first time that nationwide mortality rates for the most common category of lung cancer, non-small cell lung cancer, are declining faster than its incidence, an advance that correlates with the U.S. Food and Drug Administration approval of several targeted therapies for this cancer in recent years.

In this study, researchers looked at data for both NSCLC, which accounts for 76% of lung cancer in the U.S., and small-cell lung cancer (SCLC), which accounts for 13% (other subtypes of lung cancer that constitute the remaining share of cases were not covered in this study). In the last decade, new treatments for NSCLC have become available, including those that target genetic changes seen in some NSCLC tumors as well as immune checkpoint inhibitors that help the immune system better attack NSCLC. In contrast, there have been limited treatment advancements for SCLC.

Although death records do not distinguish between lung cancer deaths attributable to NSCLC versus SCLC, the cancer diagnosis records compiled by NCIs Surveillance, Epidemiology, and End Results (SEER) cancer registry program do distinguish between these two subtypes of lung cancer. Therefore, the researchers were able to estimate lung cancer mortality trends for these specific lung cancer subtypes by linking the lung cancer death records for each patient back to the incidence data for these patients in the SEER cancer database.

The researchers found that, in recent years, deaths from NSCLC decreased even faster than the decrease in NSCLC incidence and the decrease in deaths was associated with a substantial improvement in survival. Among men, for example, deaths from NSCLC decreased 3.2% annually from 2006 to 2013 and 6.3% annually from 2013 to 2016, whereas incidence decreased 1.9% annually during 2001 to 2008 and 3.1% annually from 2008 to 2016.

Two-year survival for men with NSCLC improved over this time, from 26% for patients diagnosed in 2001 to 35% for those diagnosed in 2014. Similar improvement was observed for women. In addition, improvements in two-year survival were seen for all races/ethnicities, despite concerns that the newer cancer treatments, many of which are expensive, might increase disparities.

The researchers had originally considered the possibility that lung cancer screening might help explain the decreases in NSCLC mortality, but their findings suggest that lung cancer screening rates, which remained low and stable, do not explain the mortality declines. Instead, the rapid decline in deaths reflects both declines in incidence (due in large part to reductions in smoking) and improvement in treatment.

In contrast, the decrease in deaths from SCLC corresponded with the decrease in incidence, and two-year survival was largely unchanged. Among men, for example, deaths declined 4.3% annually and incidence 3.6% annually. Findings were similar among women. The reduced mortality from SCLC over time, therefore, primarily reflects declines in incidence again, due largely to reduced smoking.

The researchers note that the accelerating decline in NSCLC mortality that began in 2013 corresponds with the time when clinicians began routinely testing patients for genetic alterations targeted by newly approved drugs. In 2012, the National Comprehensive Cancer Network recommended that all patients with nonsquamous NSCLC undergo genetic testing. Subsequently, genetic testing for EGFR (epidermal growth factor receptor) mutations and ALK (anaplastic lymphoma kinase) gene rearrangements which are targeted by the newer treatments increased substantially. Because immune checkpoint inhibitors were not in widespread use over the period of the analysis, the authors suspect that most of the survival benefit was attributable to effective EGFR or ALK inhibitors or other advances in therapy. The effect of immune checkpoint inhibitors on NSCLC survival is significant, which suggests that this improving trend in survival should continue beyond 2016.

The survival benefit for patients with non-small cell lung cancer treated with targeted therapies has been demonstrated in clinical trials, but this study highlights the impact of these treatments at the population level, said Nadia Howlader, Ph.D., of NCIs Division of Cancer Control and Population Sciences, who led the study. We can now see the impact of advances in lung cancer treatment on survival.

About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIHs efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCIs contact center, the Cancer Information Service, at 1-800-4-CANCER (1-800-422-6237).

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Read this article:
New treatments spur sharp reduction in lung cancer mortality rate - National Institutes of Health

A DNA test can augment or jumpstart your understanding of your family history -- from identifying close cousins all the way back to your earliest ancestors. Some tests claim to reveal your "ethnicity" -- though that's a controversial and thorny topic. And some services can shed light on your genetic predisposition for diseases and physiological traits ranging from eye color to your tolerance for cilantro.

Over the past 20 years, DNA testing has entered the mainstream, driven by higher visibility, lower prices and improving science. Back in the aughts, a do-it-yourself DNA test cost about $1,000. But in recent years, the kits have become very affordable, with a wide range of DNA testing companies -- from trailblazers such as 23andMe and Ancestry to upstarts such as Living DNA -- offering rather sophisticated analysis of your genetic makeup for as little as $75 -- or less, if you can find a deal on Black Friday or during the periodic holiday discounts throughout the year.

Now playing: Watch this: Here's how genetic genealogist CeCe Moore finds potential...

7:40

There are three types of DNA tests -- each with its own particular strengths, limitations and rationales.

Once you've been tested, each company will present you with an analysis of your geographical origin; some claim to be able to pinpoint a specific country, town or even "tribe." Some will also serve up "matches" from their DNA databases, which will give you a head start on connecting with possible relatives, and offer some degree of family tree research support. AncestryDNA, for example, offers a subscription service that includes access to hundreds of databases containing birth, death and marriage announcements, census documents, newspaper archives and other historical records.

Some companies sell tests designed for specific ethnicities or specialized kits that claim to shed light on your optimal skin care regimen or weight; others offer tests designed to identify the genetic makeup of your cat or dog. The experts I spoke to were dubious of the efficacy and value of these tests and recommended avoiding them.

If you subscribe to only one CNET newsletter, this is it. Get editors' top picks of the day's most interesting reviews, news stories and videos.

Though there's no blood involved with modern DNA testing -- you either swab the inside of your cheek or fill a small test tube with your saliva -- there are plenty of reasons to be leery of the companies that sell these kits. Your success in DNA test genealogy is largely dependent on supplying highly personal information about yourself and your relatives -- from your genetic data to your mother's maiden name, that traditional cornerstone of password security.

Concerns over data privacy and security are well-founded, and experts warn that regulation -- especially in the US -- lags far behind the technology. And you should know that some DNA testing companies may share data with pharmaceutical companies and law enforcement agencies. Bottom line: Think critically before volunteering information about your health history and familial connections to any DNA testing company or organization.

Read more: In the future, not even your DNA will be sacred

DNA testing, and genealogy more broadly, involves a complicated mixture of genetics, probabilities and guesswork. The various DNA testing services use different labs, algorithms, equipment and criteria to analyze your genetic material; though you should expect some degree of overlap between analyses from different companies, they may differ significantly. There's also an element of critical mass -- the larger the company's database, the larger the sample they use to analyze your results, and the more accurate your test result should be.

We tried some of the top DNA testing services, assessing the breadth and depth of their offerings, methodologies, reputation and price. Take a look at our recommendations below. And if you've taken any of these DNA tests, tell me about your experience with it in the comments below.

Looking for more in-depth info on DNA testing services in general? Jump to our DNA test kit explainer.

Founded in 2006, 23andMe is one of the pioneers of DNA testing for consumers. In 2017 it became the first such service to win the FDA's approval as a risk screener for diseases. It has become one of the most well-known DNA testing companies -- and well-funded, since taking in a $300 million stake from GlaxoSmithKline, which uses the company's customer data to research and design new drugs. Still, the company recently announced a round of layoffs, citing a slowdown in the DNA testing market likely caused by increasing concerns about privacy.

23andMe segments its analysis into three main categories -- health, ancestry and traits. The basic ancestry and traits test, which costs $99, includes an analysis of your genetic makeup including your regions of origin, maternal and paternal lineage and Neanderthal ancestry. Once you opt in, the company's match database -- which has more than 10 million profiles -- will identify and offer to connect you with people who share a DNA match with you.

The company's DNA health test, which starts at $199, adds information about your genetic predisposition for late-onset Alzheimer's, Parkinson's and other diseases. The service also includes analysis of your carrier status as a potential genetic carrier for disorders like Cystic Fibrosis and Sickle Cell Anemia as well as indicators for lactose intolerance and other "wellness" issues. The $499 VIP Health and Ancestry package provides priority lab processing, premium customer support and a personalized walkthrough of your results.

I found 23andMe's website and mobile app very easy to navigate and brimming with interesting, comprehensible information about both my ancestry and health as well as the science of genetics and genealogy. The main dashboard offers intuitive links to exploring your ancestry, learning about the genetic risks for health conditions, building out a family tree and connecting with relatives. Among all of the DNA tests I tried, 23andMe delivered the best introduction to my recent and ancient genealogy along with analysis of my genetic health. The only real drawback is that it does not offer integrated access to historical documents.

23andMe does provide easy access to a full range of privacy preferences and consent options, however. (That noted, 23andMe's terms of service and privacy statement is among the most extensive, exceeding 20,000 words.) You can ask the company to store your saliva sample indefinitely for future testing or have them discard it. Having signed off when I first signed up, I subsequently changed my mind about giving the company permission to share my data with researchers outside of 23andMe, and was able to retract my consent with the click of a button.

Read more:Ancestry vs. 23andMe: Which DNA testing kit is best for tracing your family history?

Founded in Utah in the 1990s, Ancestry.com -- the parent company of AncestryDNA -- started out as a publishing and genealogy company. Since then, it has had a somewhat tumultuous corporate existence, having been bought, sold, publicly traded and then purchased by private equity groups.

The company's basic DNA kit service, which costs $99, provides you with an "ethnicity estimate" derived from its proprietary sequencing techniques. It's noteworthy that the company's genetic testing, which is outsourced to Quest Diagnostics, is distinct from most other companies that use paternal Y chromosome and/or maternal mitochondrial DNA methodologies, and less is known about the particular criteria it uses.

That noted, AncestryDNA's database of 16 million profiles is the largest of all of the testing services. The company also maintains a powerful tool for searching through hundreds of historical document databases -- but any substantive research will quickly bring you to a paywall. Ancestry's databases are further bolstered by its partnership with FamilySearch.org, a genealogical records site run by the Mormon church.

An entry-level membership, which provides access to more than 15 billion US records, costs $99 for six months or $25 per month, after a free two week trial. The "World Explorer" membership, for $40 per month, broadens your access to international records, and the "All Access" tier, starting at $50 per month, includes unlimited access to Ancestry's historical and contemporary database of more than 15,000 newspapers and military records from around the world.

AncestryDNA offers a personalized health report with "actionable insights," access to genetic counseling resources and an online tool to help you map your family's health over generations. But its results are not diagnostic -- though the test result must be approved by one of the company's physicians -- and they do not have FDA approval. For now, 23andMe maintains the advantage when it comes to introductory DNA testing for health risks and genetic screening. But AncestryDNA's service is particularly well-suited for leveraging an introductory DNA analysis into deep historical research to build out a family tree.

AncestryDNA allows you to download your full DNA results profile and upload the raw data into other tools, and it provides reasonably good control over your privacy preferences, though the options are not as granular as others.

Read more: What AncestryDNA taught me about DNA, privacy and the complex world of genetic testing

Founded in 2000, FamilyTreeDNA offers a comprehensive suite of reports and interactive tools to analyze your DNA and build a family tree. With a credible claim to "the world's most comprehensive DNA matching database," FamilyTreeDNA offers all three types of tests -- autosomal DNA, Y-DNA and mtDNA. And it's the sole company to own and operate its own testing facility: The Gene-by-Gene genetic lab, located in Houston.

The company's entry-level "family ancestry" package costs $79 -- though it's frequently discounted to $59. The test results provide information about your ethnic and geographic origins, identifies potential relatives and offers access to the company's massive DNA database. I paid $275 for a broad DNA test that included analysis of my mtDNA and Y-DNA -- tests that cost $119 and $159, respectively, when you buy them individually -- as well as the "Family Finder," the company's autosomal test.

Though the user interface is a bit more complicated than what you'll find on other sites, FamilyTreeDNA provides the most complete suite of introductory tools of any provider I tested. For each type of test, you are presented with matches -- I got more than 22,000 for my autosomal DNA test -- a chromosome browser, migration maps, haplogroups and connections to ancestral reference populations, information about mutations and a link that allows you to download your raw data. Suffice to say, there are numerous threads to pull on to learn about yourself, your family and your health.

FamilyTree also offers a number of higher-end tests, for those interested in digging deeper, including a range of Y-DNA tests that will trace the path of your male ancestors and the history of your surname. The company also allows you to upload raw DNA data files from other services and transfer your autosomal information to its database to expand your universe of matches and relationships.

From a data security and privacy perspective, there are several things I find appealing about FamilyTreeDNA. The company does its own DNA testing in house, processing and storing your sample in its lab. Posted prominently on the front page of its website is a promise that the company will never sell your DNA to third parties. Like most other companies, however, FamilyTreeDNA may use your aggregate genetic information for internal research and may comply with requests from law enforcement -- unless you opt out.

The three services above are our top choices for the best DNA test. But they weren't the only ones we tested. What follows are some additional options, none of which eclipsed the 23andMe, Ancestry or FamilyTreeDNA in any significant fashion.

Based in Israel, MyHeritage was founded in 2003, and like a number of other services profiled here, started out as a genealogy software platform. Over time, it acquired a number of historical databases and eventually added DNA testing in 2016. (MyHeritage outsources its DNA analysis to FamilyTreeDNA.) In 2018, MyHeritage experienced a security breach, exposing the email addresses and hashed passwords of more than 92 million users.

MyHeritage offers a free tier of service that includes some basic family tree-building and access to excerpts of historical documents. It won't get you too far.

The basic DNA testing and analysis service, which starts at $79, includes the usual fare -- a report of your genetic makeup across the company's 42 supported ethnicities, the identification of relatives and connections to them where possible. All things considered, I preferred FamilyTreeDNA's presentation of my DNA information. But MyHeritage highlighted a first cousin living in the US, with whom I shared about 15% of my DNA, and offered to show me her family tree -- if I paid a $209 annual subscription fee.

Yes, that's expensive -- a free 14-day trial is available -- but the company maintains an impressive online database of historical documents that includes 3.5 billion profiles in addition to information about over 100 million subscribers and their collective 46 million family trees. This enormous database is powered by Geni.com, a genealogy social media site that's also MyHeritage's parent company.According to the New York Times, Geni.com has assembled "the world's largest, scientifically vetted family tree."

In 2019, MyHeritage launched a health screening test similar to the one offered by 23andMe. As part of this effort, the company partnered with PWNHealth, a network of US physicians who oversee the process. I was required to complete a personal and family health history questionnaire -- it was 16 questions -- which was then ostensibly reviewed by a doctor. Though the company says it may recommend a "genetic counseling" session administered by PWNHealth, my health results were simply delivered along with my ancestry analysis.

On the plus side, I like MyHeritage's straightforward access to a range of comprehensible privacy preferences. Still, overall, I found MyHeritage's user interface far less intuitive and more difficult to navigate than others. Though the company's offering is broad -- it's one of the few to offer a comprehensive research database of historical documents, DNA analysis and health screening -- I found the integration among them to be a bit clumsy.

Living DNA describes itself as a "consumer genealogy DNA service that does not sell or share customers' DNA or data with third parties," which gives you a sense of its priorities -- or, at least, its sense of customers' concerns. LivingDNA's headquarters in the UK may also be a factor in its distinctive mission statement, as it's subject to the more stringent data and privacy regulations of the GDPR.

LivingDNA divides its offerings in a different way than others. A $49 starter kit provides a "taster" with an introductory overview of your ancestry in eight geographical regions and access to the company's genetic matching tool, in addition to some data about personal fitness and nutrition. The full autosomal DNA testing kit costs $99 and expands the percentage-based ancestry breakdown to 80 regions and features information about maternal and paternal haplogroups. The "wellbeing package" includes reports about your physiological compatibility with vitamins, foods and exercise. And the $149 deluxe package incorporates all of this.

Recent ancestry results are presented with a breakdown of percentage by country as well as the percentage attributable to more detailed regions, as well as the origin and migration path of haplogroups. In February 2020, LivingDNA introduced an African Ancestry DNA test report that features data on 72 regions in Africa and, according to the company, "five times the detail of any other test on the market." The report is available for free to existing customers.

That noted, the company has a very limited family match database; a company representative declined to give me a specific number but said that it contained less than 1 million profiles. My wife, who took the test, returned exactly zero matches. So, if you're looking to identify and make connections with relatives, there are better choices in the market. That noted, LivingDNA has a very solid reputation for both the quality of its DNA analysis and privacy terms among experienced genealogists.

There are a number of companies -- including Full Genomes, Veritas Genetics, Nebula Genomics and Dante Labs -- that can sequence all of your DNA, otherwise known as your genome. This level of analysis is appropriate for advanced users only. Not only is it expensive -- these tests can run into the thousands of dollars, in some cases -- it requires a sophisticated understanding of both genetics and a range of technical tools required to explore and interpret your results.

The least expensive whole genome tests cost about $300. For example, Full Genome's 30X test -- which scans every targeted location of your genome 30 times on average -- is considered the standard for a clinical analysis. It costs $1,800.

For most people, the main rationale for sequencing the whole genome is to dive deep into your genetic health outlook. You can glean your personal risk factors for diseases, drug sensitivities and your status as a carrier; that is, what you might pass on to your kids. But there are also plenty of applications for advanced genealogical projects.

All of these efforts can also be undertaken -- to a less intense degree -- with some of the more affordable options outlined above. But whole genome sequencing provides a significantly more comprehensive, accurate and high resolution analysis.

If you want to dip your toe into this realm. you might want to start with Nebula Genomics. You can also upload an existing DNA sequence from Ancestry or 23andMe's DNA database and get Nebula's reports at a reduced price.

HomeDNA sells testing kits under a number of brands, including DNA Origins, and has a retail presence at Walmart, CVS, Rite Aid and Walgreens. The company's tests claim to combine genetic research and "ancestral tracking" techniques that can identify the town or village where your ancestors originated with a high degree of accuracy. Many experts dispute these claims.

The company offers a range of ancestry testing services starting at $69. That's the price point for the maternal and paternal lineage kits and the "Starter Ancestry Test," which uses DNA markers to develop an estimate of your origins in Europe, Indigenous America, East Asia and Sub-Saharan Africa -- and shows you the modern population groups that share your DNA. The $124 "Advanced Ancestry Test" expands the analysis to 80,000 autosomal genetic markets, 1,000 reference populations and 41 gene pools.

I'll note that the HomeDNA test kit contained no warning about not eating or drinking for any period of time prior to taking the test -- unlike every other kit I used. And of the four swabs the company sent, one broke. The test kit just didn't seem as rigorously hygienic as the others.

For $199, HomeDNA claims that the Asian Edition of its GPS Origins Ancestry Test can analyze 17 Asia-specific gene pools and hundreds of Asia-specific reference populations. In addition to a $164 paternity kit, the company also sells a variety of specific kits to determine your sensitivities to particular animals and foods, one to help you achieve a healthy weight, and another that promises to "unlock your skin's full potential."

For $39, the company will allow you to upload a raw data file from another DNA testing service and pinpoint your origin to a particular town or city. There are also kits to help you identify you screen your dog or cat for genetic diseases and traits.

But this company doesn't have a sterling reputation in the genetic genealogy world. When we recently spoke with Debbie Kennett, a genetic genealogist from University College London, she referenced the company's notoriety for delivering "bizarre results" and expressed doubt about the efficacy of its specialized tests for particular ethnic groups. HomeDNA did not respond to CNET's inquiry about its testing process or results.

And the HomeDNA reports don't stack up particularly well against those returned by other companies. Results are summarized on a single webpage, though you also get a PDF that certifies that you've "undergone DNA testing" and shows the continents and countries where your DNA originates. The company also throws in a boilerplate 20-page explainer about DNA science and technology. HomeDNA does not offer access to any matching databases -- so there's no obvious next step or any actionable data that comes with your results. Given this, I'd recommend choosing a different DNA testing service.

Claiming to have the most comprehensive database of African lineages, African Ancestry promises to trace its customers' ancestry back to a specific country and identify their "ethnic group origin." But a number of experienced genealogists have cited issues with this company's marketing claims and science.

Unlike most other companies, African Ancestry doesn't offer an autosomal DNA test. Instead, it offers an mtDNA test or a Y-DNA test (for males only). In contrast to your standard DNA analysis, African Ancestry's report doesn't provide the percentage of DNA that's likely to have originated across a range of regions. Instead, African Ancestry claims to trace your DNA to a specific region of Africa.

According to experts, however, African Ancestry's DNA tests come up short. As explained in a blog post by African American genetic genealogist Shannon Christmas, the company's methodology simply doesn't analyze a sufficient number of DNA markers to deliver on its marketing promises.

Furthermore, he writes, "Ethnicity is a complex concept, a concept not as rooted in genetics as it is in sociopolitical and cultural constructs. There is no DNA test that can assign anyone to an African ethnic group or what some refer to as an 'African tribe.'" African Ancestry isn't the only company that claims to be able to determine your ethnicity or "ethnic group of origin." But its claim to narrow things down to a single "tribe" of origin is overblown, as any African tribe would ostensibly contain multiple haplogroups.

In an email to CNET, African Ancestry responded: "African Ancestry makes it clear that ethnic groups are social and cultural groupings, not genetic ones. However, based on extensive genetic research of African lineages performed by African Ancestry's co-founder and Scientific Director (who holds a Ph.D. in Biology and specializes in human genetics), we find that contrary to laymen's beliefs, there are ethnic groups that share genetic lineages. Our results pinpoint genetic lineages that share the same genetics as our test takers. Given the vast number of lineages in our African Lineage Database, we are able to provide the ethnic groups of the people with that shared lineage."

The company's PatriClan Test analyzes eight Y-chromosome STRs and the YAP, which it says is a critical identifier for African lineages; and the MatriClan Test analyzes three regions of the mitochondrial DNA: HVS1, HVS2 and HVS3. But though these tests offer lower-resolution results than others, African Ancestry's services are considerably more expensive. The company's Y-DNA test and mtDNA tests cost $299 each -- or you can take them both, and get an eight-pack of "certificates of ancestry" and a four-pack of t-shirts, for $679.

On the plus side, African Ancestry says that it does not maintain a database of customer information and that it will not share or sell your DNA sequence or markers with any third party -- including law enforcement agencies. The company's terms and conditions run to just over 2,200 words, making them considerably more concise than the disclosure statements of most other companies we included in this roundup. And African Ancestry promises to destroy your DNA sample after your test results are delivered.

That said, even if you accept the company's take on tribal and ethnic genetic markers, African Ancestry remains too expensive to recommend at its current price.

If you're using a home DNA testing service, you're likely looking for one of three things:

Ancestry and family history: The first big draw of a full DNA test is that you'll get a detailed breakdown on ancestry and ethnicity, and the migration patterns of your common ancestors. Spoiler alert: Your ethnic background may be radically different than you think it is. You'll also find out what a haplogroup is.

Relative identification: With your permission, some DNA services will let you connect with relatives you never knew you had -- other folks with matching DNA who have used the service and likewise given their permission to connect to possible relations.

Health and disease info: DNA testing can also indicate which conditions for which you may have a preponderance. It's a controversial feature, to be sure. Knowing that you have a genetic predisposition to a certain form of cancer may make you more vigilant for testing, but it may also lead to increased stress -- worrying about a potential health condition that may never develop, even if you're "genetically susceptible" to it. The possibility of false positives and false negatives abound -- any such information should be discussed with your doctor before you act upon it.

Afraid of needles and drawing blood? Good news: That's not an issue with these tests. All you need to do is spit into a vial or rub a swab in your mouth -- all the genetic data needed for these tests is present in your saliva -- and ship the DNA sample to the company for analysis.

The reason that a saliva sample works as well as blood (or hair follicles or skin samples) is that your DNA -- which is short for deoxyribonucleic acid -- is present in all of them. It's the basic genetic code present in all of your cells that makes up your key attributes, from the color of your eyes to the shape of your ears to how susceptible you are to cholesterol.

The key terms you need to know when comparing DNA testing services are:

SNP (single nucleotide polymorphism): Genotyping is done by measuring genetic variation. One of the more common is SNP genotyping, which measures the variations of a single nucleotide polymorphism. The more of these a company measures, the more granular the analysis.

Autosomal DNA testing: An autosomal test that's effective for men and women, and which traces lineage back through both maternal and paternal bloodlines.

Y-DNA: The Y-DNA test can only be administered to men, and traces DNA back through the patrilineal ancestry -- basically from father to grandfather to great grandfather and so on.

mtDNA: The mtDNA is matrilineal and lets you trace your ancestry back through your mother, grandmother, great grandmother and so on.

David Gewirtz contributed to this story. The current version is a major update of past revisions, and includes hands-on impressions of most of the services listed.

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Read more:
Best DNA test in 2020: 23andMe vs. AncestryDNA and more - CNET

New Jersey, United States,- The most recent Direct-to-consumer Genetic Testing Market Research study includes some significant activities of the current market size for the worldwide Direct-to-consumer Genetic Testing market. It presents a point by point analysis dependent on the exhaustive research of the market elements like market size, development situation, potential opportunities, and operation landscape and trend analysis. This report centers around the Direct-to-consumer Genetic Testing business status, presents volume and worth, key market, product type, consumers, regions, and key players.

The COVID-19 pandemic has disrupted lives and is challenging the business landscape globally. Pre and Post COVID-19 market outlook is covered in this report. This is the most recent report, covering the current economic situation after the COVID-19 outbreak.

Key highlights from COVID-19 impact analysis:

Unveiling a brief about the Direct-to-consumer Genetic Testing market competitive scope:

The report includes pivotal details about the manufactured products, and in-depth company profile, remuneration, and other production patterns.

The research study encompasses information pertaining to the market share that every company holds, in tandem with the price pattern graph and the gross margins.

Direct-to-consumer Genetic Testing Market, By Type

Direct-to-consumer Genetic Testing Market, By Application

Other important inclusions in the Direct-to-consumer Genetic Testing market report:

A brief overview of the regional landscape:

Reasons To Buy:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Fiberglass Mold Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Food Colors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Gelcoat Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Hydraulic Fluid Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Ion Exchange Resin Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Link:
Direct-to-consumer Genetic Testing Market 2020 Size by Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies and Forecast...

Note: Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Direct-to-consumer Genetic TestingMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Direct-to-consumer Genetic Testing Market Players to battle Covid-19 Impact.

The Direct-to-consumer Genetic TestingMarket report is compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in future. It offers detailed research and analysis of key aspects of the Direct-to-consumer Genetic Testing market. Readers will be able to gain deeper understanding of the competitive landscape and its future scenarios, crucial dynamics, and leading segments of the global Direct-to-consumer Genetic Testing market. Buyers of the report will have access to accurate PESTLE, SWOT and other types of analysis on the global Direct-to-consumer Genetic Testing market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries. Players can use this study to explore untapped Direct-to-consumer Genetic Testing markets to extend their reach and create sales opportunities.

The study encompasses profiles of major Companies/Manufacturers operating in the global Direct-to-consumer Genetic Testing Market.Key players profiled in the report include:23andMe, MyHeritage, LabCorp, Myriad Genetics, Ancestry.com, Quest Diagnostics, Gene By Gene, DNA Diagnostics Center, Invitae, IntelliGenetics, Ambry Genetics, Living DNA, EasyDNA, Pathway Genomics, Centrillion Technology, Xcode, Color Genomics, Anglia DNA Services, African Ancestry, Canadian DNA Services, DNA Family Check, Alpha Biolaboratories, Test Me DNA, 23 Mofang, Genetic Health, DNA Services of America, Shuwen Health Sciences, Mapmygenome, Full Genomes and More

Get PDF Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, List of Tables & Figures, Chart):https://www.marketinforeports.com/Market-Reports/Request-Sample/145059

Segmental Analysis:The report has classified the global Direct-to-consumer Genetic Testing market into segments including product type and application. Every segment is evaluated based on share and growth rate. Besides, the analysts have studied the potential regions that may prove rewarding for the Direct-to-consumer Genetic Testing manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, there by helping market players to gain deep insights into the overall Direct-to-consumer Genetic Testing industry.

Key Types:Diagnostic ScreeningPrenatal, Newborn Screening, and Pre-Implantation DiagnosisRelationship Testing

Key End-Use:OnlineOffline

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketinforeports.com/Market-Reports/Request_discount/145059

The authors of the report have analyzed both developing and developed regions considered for the research and analysis of the global Direct-to-consumer Genetic Testing market. The regional analysis section of the report provides an extensive research study on different regional and country-wise Direct-to-consumer Genetic Testing industry to help players plan effective expansion strategies.

Regions Covered in the Global Direct-to-consumer Genetic Testing Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2025

For More Information:https://www.marketinforeports.com/Market-Reports/145059/Direct-to-consumer-Genetic-Testing-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/145059/Direct-to-consumer-Genetic-Testing-market

Get in Touch with Us :Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: [emailprotected]Website: http://www.marketinforeports.com

Read more here:
Impact of COVID-19 on Global Direct-to-consumer Genetic Testing Market with Covid-19 Effect Analysis | likewise Industry is Booming Globaly with Key...